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TECHNICAL GUIDANCE FOR THE COMPLETION OF A SUMMARY 
NOTIFICATION DOSSIER FOR A NEW CHEMICAL SUBSTANCE 
UTILISING THE STRUCTURED NOTIFICATION INTERCHANGE 
FORMAT (SNIF) 
This document has been prepared by the Competent Authorities of the EU Member States for the 
implementation of Directive 67/548/EEC as guidance for those preparing the notification of a 
new chemical substance in accordance with EU Directive 67/548/EEC, as amended for the 
seventh time by EU Directive 92/32/EEC (ref.: O.J. L 154, 5 June 1992). Prospective notifiers of 
a new substance are advised to always contact the Competent Authority (CA) in the appropriate 
country before starting work on preparing a notification dossier. Any questions resulting from 
this guidance should be addressed to the relevant CA. This document primarily addresses the 
completion of the summary notification dossier; questions on other aspects of the Directive 
should again be addressed to the relevant CA. 
This text has no legal value. The requirements in EU Directive 67/548/EEC are paramount 
and take precedence over this guidance. 
 
 
GENERAL INTRODUCTION: 
 
1. TECHNICAL DOSSIER TO BE SUBMITTED 
This is a guidance note for completing a standardised summary form for the notification of a new 
chemical substance in quantities of > 10 kg per annum in the European Union, Norway, Iceland 
and Liechtenstein (known collectively as the European Economic Area (EEA)) according to 
Annex VII A, B, C, or D, or Annex VIII of Directive 67/548/EEC. The summary form will be a 
part of the technical dossier required for the notification of a new substance. In addition to the 
summary form the technical dossier should include all test reports, the chemical structure, 
spectra, a proposal for a material safety data sheet in the event that the notified substance should 
be classified and labelled, and possibly a draft risk assessment. Any risk assessment should 
follow the principles contained in Directive 93/67/EEC. Notifiers should consult the relevant 
national authorities for specific requirements on language to be used and the number of copies of 
the notification dossier to be provided. All CAs prefer the summary to be submitted on an 
electronic format (see item 4 of the General Introduction); in some countries this is a legal 
requirement. 
In general, the potential for exposure to a notified substance is related to the quantity on the 
market. Therefore, as the supply level and potential for exposure increase, the potential for 
adverse effects also increases. Consequently there is a need to obtain more information on 
hazards of the substance, and hence the tonnage-related testing requirements of Directive 
67/548/EEC (known as the Dangerous Substances Directive). The levels of supply at which 
further testing may either be requested or become necessary are described in Article 7(2) of 
Directive 92/32/EEC (the seventh amendment to Directive 67/548/EEC). 
The following categories are defined (in Directive 92/32/EEC): 
- a reduced notification according to Annex VII C of the Directive for substances marketed in 
quantities between 10 and 100 kg per year per manufacturer (or < 500 kg cumulatively); 
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- a reduced notification according to Annex VII B of the Directive for substances marketed in 
quantities between 100 and 1000 kg per year per manufacturer (or < 5000 kg cumulatively); 
 
- a base set notification according to Annex VII A of the Directive for substances marketed in 
quantities equal or more than 1000 kg per year per manufacturer (or > 5 tonnes 
cumulatively). 
An overview of the relevant sections to be completed for a notification according to one of these 
categories is given in Annex 1 to this guidance. 
The general requirements for further testing at specified higher levels of supply are set out in 
Annex VIII of Directive 67/548/EEC, the latest update of which is contained in Annex VIII of 
Directive 92/32/EEC. Nevertheless, tests in addition to those specified in Annex VIII can be 
requested, or submitted for assessment. 
 
2. TEST METHODS AND TESTING STRATEGIES 
Approved test methods, to provide results which can permit further classification of notified 
substances, are described in Directives 87/302/EEC, 92/69/EEC and 96/54/EEC. However, 
most OECD test methods are equally acceptable, and in some circumstances, other validated and 
scientifically accepted methods can be used provided adequate justification is presented or, 
where there is no approved method for a particular objective. 
A comprehensive guide on the testing strategies available to assist the progressive collection of 
information, in order to Conduct risk assessment of notified substances, is provided in the 
'Technical Guidance Document in support of the Commission Directive 93/67/EEC on Risk 
Assessment for New Notified Substances and the Commission Regulation (EC) 1488/94 on 
the Risk Assessment for Existing Substances (known as the 'Technical Guidance')'. This has 
been published by the Office of Official Publications of the European Communities EC 
catalogue numbers CR-48-96-001-EN-C, CR-48-96-002-EN-C, CR-48-96-003-EN-C, CR-48-
96-004-EN-C. It is recommended that Competent Authorities and Notifiers refer to this guidance 
in the interest of promoting standardisation of hazard identification and risk assessment 
procedures. This document has been published in four parts (the EC catalogue numbers are CR-
48-96-001-EN-C, CR-48-96-002-EN-C, CR-48-96-003-EN-C, CR-48-96-004-EN-C). 
 
3. ADDITIONAL TESTING POST-BASE SET AND AT 
LEVEL 1 AND LEVEL 2 
POST-BASE SET 
It is important to note that one of the outcomes of the environmental risk characterisation carried 
out at the Base Set in accordance with Directive 93/67/EEC, may indicate the need to carry out 
certain Level 1 studies immediately, rather than wait for the tonnage trigger to be reached. 
LEVEL I 
Article 7(2) of Directive 92/32/EEC may require additional (eco)toxicity testing when the 
tonnage placed on the market reaches 10 tonnes per annum or 50 tonnes total; the tests which 
may be required are listed in Annex VIII. When the tonnage reaches 100 tonnes per annum or 
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500 tonnes in total, all the tests listed in Annex VIII will normally be required. There may be 
technical reasons why a particular study cannot be performed, for example if it is not appropriate 
or an alternative study is preferable. In these cases it is for the notifier to provide the competent 
authority with full justification for any deviations from the requirements. 
LEVEL II 
Article 7(2) of Directive 92/32/EEC also makes provision for further testing when the quantity 
placed on the market reaches 1000 tonnes per annum or 5000 tonnes in total. The testing 
programme is outlined in Annex VIII and reflects the possible need for further information. This 
information maybe necessary in the light of the results obtained from testing at the Base Set and 
Level 1. 
 
4. SNIF PROFORMAS 
The Structured Notification Interchange Format (SNIF) is the computer-based system for the 
exchange of essential notification information, adopted throughout the European Union (EU) in 
June 1992. The Competent Authority should be contacted to obtain the required SNIF software. 
This guidance is intended to help standardise the format, quality and consistency of data 
collection in SNIF for studies conducted at base set level and at higher levels of supply. 
In the following text, the index numbers for the studies and the format for collection of 
information, conform to the style of those in the SNIF software application, which is based on 
the Summary Notification Dossier (SND) document XI/85/90 (available from the relevant CA). 
Data may be viewed or edited online, using the SNIF software, or offline, using a printout of the 
SNIF information. 
The procedures described below are intended to satisfy either approach, since edits collected on 
paper must ultimately be transferred back into the software application. 
In some cases, e.g. mutagenicity testing, a single proforma is utilised for several test methods. 
For others, the proforma is designed specifically for an individual test method. There is also a 
draft proforma for ‘Other tests' (index 4.7), which is intended to be flexible and to permit data 
collection for additional tests. 
In entering data to the proformas, all descriptions of toxic signs, observations and general 
comments should be as clear, concise and precise as possible. Also, in addition to entries of 
positive toxic effect, entries of 'no toxic effect', or, where appropriate, 'not examined' should be 
included to maintain a complete and consistent record. Nevertheless, in the SNIF software 
application, no entries are obligatory (this includes tabular entries). However, if any field is left 
blank an entry may be necessary under ‘Comments' to explain why. 
Under Method, care should be taken to make clear if a test method is in 96/54/EEC, 92/69/EEC, 
87/302/EEC, OECD test methods, or from a published paper. 
Under Body responsible for test, entries must be in the recognised format. SNIF contains a pre-
defined list of Test Facilities together with selection codes for entry of this information. 
Under Comments it is important to note if a study is unacceptable and to indicate why. Also, 
scientific justification should be available for any deviation from an approved test method, or to 
support a non-standard specialised test method. 
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Additionally, classification and labelling (C&L) recommendations are normally not included in 
Comments, except in circumstances that require clarification, e.g. R48 is justified, as there is a 
need to indicate whether Harmful (Xn) or Toxic (T) is appropriate for the label; whereas R61 is 
not justified as it indicates significant toxic effects observed in the dams. 
In the guidance below, the standard proforma is represented in bold text, and guidance on 
responses is represented in normal text. Fields normally required, at levels 1 and 2 are given in 
italics. 
Comment on SNIF proformas 
The proformas presented in the guidance below are those currently in existence in the 
SNIF software. It is nevertheless important to note that some of these proformas are not 
adequate for complete data collection in a common format. In many circumstances it is, 
therefore, necessary to include additional information in the 'Comments' section. 
In view of this, it is expected that as the use of SNIF proformas increases, they will be 
updated where necessary to make them more user friendly, e.g. important information will 
be prompted for and therefore be less likely to be overlooked. 
Contact the Competent Authority for obtaining the most recent version of the SNIF. 
 
5. CONSULTATION OF THE COMPETENT AUTHORITY 
BEFORE CARRYING OUT ANIMAL TESTING 
Before carrying out animal testing, for the purpose of collecting test data for the notification of a 
new substance, the potential notifier must enquire of the Competent Authority as to whether the 
substance has already been notified and, if so, the name and the address of the first notifier. 
Enquiries should be made, in the first instance, to the Competent Authority where the 
notification is to be made. In order to ensure that the enquiry is genuine and not simply a 
competitor trying to identify the name or interests of other suppliers, the enquirer must provide 
the following information: 
 
1. Name, address and contact person of the potential notifier if enquiry is via a third party (for 
guidance see notes to section 0.2.10, page 6 of this guidance). 
2. Name and address of the manufacturer (for guidance see notes to section 0.2.20). 
3. IUPAC name or description if a UVCB substance (for guidance see notes to section 
1.3.10.10/20). 
4. CAS number (for guidance see notes to section 1.3.10.30/40). 
5. Empirical and structural formula; stereochemistry for optical geometric isomers (for 
guidance see notes to section 1.3.10.50/60). 
6. Nature and percentage of impurities and additives (for guidance see notes to section 
1.3.20/40). 
7. EEC number of substance, if believed to be on ELINCS. 
8. Analytical and spectroscopic data (for guidance see notes to section 1.3.00 of the summary).  
9. Intended use (for guidance see notes to section 2.1.00 of the summary). 
 
The key items are the analytical and spectral data and intended use. These demonstrate that the 
enquirer has taken time to obtain a sample of the substance and identify a market for it. The other 
information follows from the former and is to aid the Competent Authority in ensuring that a 
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complete search of the records held is possible. It also confirms that the substance is sufficiently 
identical in terms of purity and impurities to that originally notified to allow the 'sharing of data'. 
 
6. CONFIDENTIALITY 
In conformity with Article 19.1. of Directive 92/32/EEC, notifiers may indicate which 
information in the notification dossier they wish to be treated as confidential. If confidentiality is 
requested for any item, justification must be given and the Competent Authority receiving the 
dossier will have the final decision on the confidentiality or otherwise of information in the 
dossier. If information is accepted as being confidential, it shall be kept secret by the 
Commission and the Member States as described in Article 19.2 of the Directive. However, it 
should be understood that Article 19.1 limits those items of information for which confidentiality 
can be claimed. In the summary dossier the notifier may request confidentiality by ticking the 
column, where it exists, alongside the information he wishes to be regarded as confidential. 
The notifier should justify in the summary form, or in a separate annex, their claim to keep the 
indicated information confidential. The information given should be sufficient to evaluate the 
justification of the confidentiality claim. Possible confidential information can be divided into 
five main categories, namely: 
- Chemical identity of the substance, 
- Impurities, 
- Uses and desired effects of the substance,  
- Volumes on the market, 
- Names of bodies responsible for the tests. 
The justification for the claim for confidentiality should be given for each of these main 
categories, if appropriate, in a separate annex. When the summary has been provided in the SNIF 
format, the claims for confidentiality should be justified sufficiently, in a separate annex for each 
of the above mentioned main categories. When the information is claimed confidential without a 
sufficient explanation, the Competent Authority may decide that the claim for confidentiality is 
not justified. 
 
7. APPLICATION FOR A PROCESS-ORIENTATED 
RESEARCH & DEVELOPMENT EXEMPTION 
In conformity with Article 13.2 of Directive 92/32/EEC, substances solely intended to be used 
for process orientated research and development (R&D) purposes, with a limited number of 
registered customers, in quantities which are limited to that needed for process-orientated R&D, 
qualify for an exemption of one year. The notifier should justify the request for an exemption of 
one year by providing information on the research and development proposed (Annex 6 of this 
guidance contains a draft list of the sort of information that may be required. Notifiers should 
contact the Competent Authority who will detail the up-to-date information they require). A 
submission for the exemption is required in each Member State where supply is to occur. 
Furthermore, the notifier should communicate to the Competent Authority in each Member State 
where supply is to occur any additional information. In addition notifiers should consult the 
national regulations of the relevant Member State(s) or contact the Competent Authorit(y)(ies) 
for national requirements. 
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On granting an exemption of one year, the substance must not exceed the quantity stated in the 
exemption and the deferred notification should normally be submitted at the end of the 
exemption period. 
In exceptional circumstances the exemption may be extended for a second year provided that the 
notifier can demonstrate, to the satisfaction of the CAs, that such an extension is justified. Where 
possible this justification should be included in the original application for an R&D exemption. 
 
8. GENERAL POINTS ON COMPLETING THE SUMMARY 
FORM 
8.1 Tests should be carried out on the substance including any essential additives (for the 
stability of the substance) and impurities it normally contains, but excluding gross 
amounts of water, mineral oil or other solvents that are sometimes present in the 
substance eventually marketed. Ideally, one batch of substance should be used for all 
tests. If for any test the composition of the substance is different from that quoted in 
sections 1.3.10 to 1.3.40 then full details should be provided. 
8.2 Where appropriate, details of the stability of the substance under storage conditions prior 
to testing and in any vehicle used during testing, should be specified in the relevant 
section(s) of the summary document. In particular, where the long-term stability is in 
doubt the composition must be checked (as in item 1.4.00) before testing. 
8.3 Phrases such as (under 3.0.60) “insoluble in water” are discouraged. A limit test should 
be performed under such circumstances so that a positive response, such as "< 0.1 mg/l 
(analytical limit)", can be entered. 
8.4 All tests should be conducted in accordance with Annex V methods (Directive 
87/302/EEC, 92/69/EEC and 96/54/EEC). Exceptions to this should mainly be as a 
consequence of changes to OECD test guidelines or developments in the field of animal 
welfare. The entry under “Method” would normally, therefore, be Annex V (quoted as 
the Directive number). If a test has been performed that deviates from Annex V/OECD, 
or if a required test has not been performed, the nature of the differences must be 
indicated under “Method” and justification for the deviation or the omission, acceptable 
to the Competent Authority, must be provided under “Comments”. 
8.5 All testing must be performed in accordance with the principles of Good Laboratory 
Practice (GLP) (Directive 87/18/EEC, Official Journal of the European Communities, 17 
January 1987, L 15, p29). Test reports should contain suitable signed GLP and Quality 
assurance (QA) statements. 
8.6 Labelling proposals should be for the substance as tested and not preparations and should 
be entered at Section C. Criteria for labelling are given in Directive 93/21/EEC as 
published in the Official Journal of the European Communities, 4 May 1993, L110. 
8.7 Notifiers are encouraged to consult the relevant Competent Authority in the Member 
State in which they intend to notify if they have any queries (e.g. on test protocols). 
8.8. In this guidance the sections related to the additional test data that may be required for 
level 1 and level 2 are presented in 'Italics'. These sections can be ignored for the base-set 
notification. 
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DETAILED COMMENTS ON COMPLETING THE SUMMARY DOSSIER 
SECTION 0 DETAILS OF THE NOTIFICATION 
Most of the information requested in section 0 must not be completed by the notifier. It is clearly 
indicated which sections are relevant for the notifier to complete. 
 
0.1.00 DETAILS OF THE NOTIFICATION 
0.1.10 General information 
Full dossier 
Indicate whether the notification is the first notification of the substance for which a full base set 
must be provided, or the notification refers to a previous submitted notification for which only 
section 0 suffice to complete. 
There are several cases for which completing only section 0 is not sufficient: 
- In the case of only a previous notification under the 6th Amendment also the relevant 
sections with additional information required under the 7th Amendment must be provided. 
- When a repeated notification refers to a previous submitted notification at lower level, the 
relevant sections related to the required additional information must be completed. 
 
Member state of notification 
 
Date of notification 
Only to be completed by the Competent Authority 
 
Lead dossier 
 
Previous notification numbers 
 
Name of the substance (Trade name or other identification name) 
The notifier should indicate clearly the names to appear in the European List of Notified 
Chemical Substances (ELINCS). 
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0.2.00 DETAILS OF THE NOTIFIER AND THE MANUFACTURER 
0.2.10 Notifier 
Give the name and address of the notifier, and the name of the contact person responsible for the 
notification. Indicate whether the notifier is the domestic manufacturer, an importer of the 
substance manufactured outside the EEA, or a sole representative for the notification of the 
substances manufactured outside the EEA. In the case of the importer or the sole representative, 
complete section 0.2.20 
 
0.2.20  Manufacturer (in the case of import of the substance) 
When the notifier is an importer or a sole representative, give in this section the name(s) and 
address(es) of the manufacturer(s) outside the EEA, and the name(s) of the contact person(s). In 
the case of more than one manufacturer, the notifier must provide information to show that the 
chemical identities of the substances produced by the manufacturers do not deviate from the 
chemical identity of the substance to be notified. 
Importer(s) for the sole representative 
When the notifier is a sole representative complete this section. 
 
0.3.00  NAME TO BE INCLUDED IN ELINCS 
To be completed by the notifier (see section 0.1.10). 
0.3.10  View of the authority with regard to the publication 
To be completed by the competent authority. 
0.3.20  ELINCS chemical name 
To be completed by the European Chemicals Bureau. 
0.3.30  EEC number 
To be completed by the European Chemicals Bureau. 
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0.4.00 CLASSIFICATION AND LABELLING 
To be completed by the Competent Authority. This section gives the view of the Competent 
Authority with regard to the classification and labelling of the substance. 
0.4.10 Classification 
0.4.20 Labelling 
 
0.5.00 COMMENTS OF THE COMPETENT AUTHORITY 
To be completed by the Competent Authority. The Competent Authority gives in this section its 
comments and observations with regard to the information provided in the notification including 
the acceptance, and comments on the proposal by the notifier for the classification and labelling. 
Technical details related to specific tests must be given in the "Comments" sections of the 
respective test. Errors or misinterpretations in the results might be noted in this section, but must 
be corrected as much as possible in the respective sections. 
 
0.6.00  COMMENTS OF THE COMMISSION 
To be completed by the European Chemicals Bureau. 
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SECTION A  TECHNICAL DOSSIER 
SECTION A1  IDENTITY OF THE SUBSTANCE 
 
1.1.00  NAME 
1.1.05.10 Mixture 
Indicate whether the substance is a mixture or a substance as such. Detailed information of the 
composition must be given in section 1.3. 
Name in the IUPAC nomenclature 
Notifiers should be aware that where the Directive requires the disclosure of the chemical name 
for the purpose either of publication in ELINCS (the European List of New Chemical 
Substances, see Commission decision of 21 December 1984, published in the Official Journal on 
2 February 1985, No L 30, page 33) or, in Annex 1, it is the information given in this section 
which will be used in determining how the substance will be described. 
1.1.05.20 Trade name(s): 
Include all trade names and/or other public identifiers under which the substance will be 
marketed in the EEA. For dyestuffs, the Colour Index Name will suffice if the substance will be 
marketed under this name alone. Whether a formal registered trade name or, in its absence, 
simply an identifier, in the eventual summary this item will be entered under the title “Trade 
Name(s)”. 
1.1.05.30 Other names 
E.g. company code number or internal name. 
1.1.05.40 CAS-number (in the case of a mixture) 
If available. If not yet allocated leave blank or enter NYA. 
1.1.05.50 Degree of purity 
Give the typical percentage purity with the upper and lower limit for typical commercial batches 
of the substances. If the substance is a complex reaction mixture, give the typical percentage 
purity with upper and lower limits for each of the main components. 
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1.3.00  COMPOSITION OF THE SUBSTANCE (GENERAL) 
The information given in this section should be for typical batches of the substance. It is 
recognized that notified substances will inevitably include some impurities (see section 1.3.20) 
and if necessary some essential additives (see section 1.3.40). However, the substance tested 
should not include gross amounts of separable solvents nor substances added subsequently to 
make a preparation. 
1.3.10  Component(s) 
1.3.10.10/20 IUPAC-name(s) 
Give the IUPAC-name in the national language and in English of the component(s). 
1.3.10.30/40 CAS-number/name 
Give the CAS-number(s) and the name according to the CAS-nomenclature of the component(s), 
if available, otherwise leave blank or enter NYA. 
1.3.10.50/60 Empirical (molecular) and structural formula(e) of the components 
Strictly the molecular formula - and should be given according to the (traditional) Hill system 
and also according to the CAS system, where this differs from the Hill system formula. For 
UVCB compounds/products by process, an empirical formula should be determined. In the case 
of a mixture, strictly the molecular formulae for each component can be given or used to explain 
the structure given (e.g. variation in counter-ions, possibility of isomers etc.). 
Comment, if no structural formula can be given. 
1.3.10.70 Molecular weight of the substance 
Give the molecular weight of the notified substance 
1.3.10.100 File name 
When the structural formula has been prepared by using sophisticated software capable to export 
a MOL-file (e.g. ISIS and CHEM-X) the structure might be submitted on diskette. Give in this 
section the name of the MOL-file on diskette. This is not currently in use. 
1.3.10.110 Smiles code 
If available, give the structural name according to the SMILES-notation. 
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1.3.10.120/130 Polymer identity 
Both the average molecular weight (Mn) and the molecular weight distribution must be 
provided. These can be determined using GPC. Distribution curves must be provided in the form 
of a table, or as a figure (differential frequency or sum percentage against log M). 
1.3.10.140 Typical concentration of the component(s) 
Give the percentage of the component(s). Indicate whether by weight (preferred) or volume 
giving values for the substance tested and, where possible, the expected commercial range. 
Note: Composition of the used test batches of the substance(s) must be provided in section 2.6. 
Give the typical percentage purity with the upper and lower limit for typical commercial batches 
of the substances. If the substance is a complex reaction mixture, give the typical percentage 
purity with upper and lower limits for each of the main components. 
1.3.20  Identity and percentage of impurities 
Give the IUPAC-name(s), nature, CAS-numbers, if available, and percentage of the main 
impurities including isomers and by-products and the total number of unidentified impurities. 
NR minor or, even trace, impurities should be included if they have, or if they may reasonably be 
suspected to have, toxicological importance; and for labile substances the nature of resulting 
degradation products should also be stated. Indicate whether by weight (preferred) or volume 
giving values for the substance tested and, where possible, the expected commercial range (as for 
1.3.10.). 
Note: Composition of the used test batches of the substance(s) must be provided in section 1.5. 
Provide the following information (1.3.30, 1.3.32 and 1.3.33) on paper, as they are not present in 
the SNIF proforma. 
1.3.30  Polymer starting materials and end groups 
Give the identity and percentage of starting monomers and substances, which will be tied in the 
polymer material, IUPAC-name, and CAS-number if available 
1.3.32 End groups and reactive groups 
IUPAC-name, CAS-number if available and frequency of end (reactive) group(s) 
(number/repeating unit) 
1.3.33 Identity of monomers not reacted 
IUPAC-name, CAS-number if available and percentage by weight (preferred) or volume giving 
values. 
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1.3.40  Essential Additives 
Give the IUPAC-name(s), nature, function, CAS-number(s), if available, and approximate 
amount (percentage or ppm) of any stabilizing agent, inhibitor or other essential additive 
required for the stability [isolation] of the substance, but exclude substances added subsequently 
to make a formulation or a preparation. 
1.3.50 Spectral Data 
Indicate which have been measured in order to confirm the structure given, noting significant 
wavelength or other data here and attaching annexes as appropriate. Give solvent used and/or 
other essential details as indicated. Clear copies (rather than originals) with scales properly 
marked and for 1H NMR spectra (see under c) the integration curve should be provided; 
concentrations used should ensure the most intense substance-related peaks approach the full-
scale mark; the intensity of weak NMR peaks should be increased vertically and complex pattern 
expanded. For each type of spectrum the following information should be indicated on the 
spectrum itself. 
a) UV/Visible spectrum 
The identity of the substance; solvent/concentration; range; position (and epsilon value) 
of main peaks; effect of acid; effect of alkali. 
b) IR spectrum 
The identity of the substance; medium; range; results. 
c) NMR spectrum 
The identity of the substance; nucleus/frequency; solvent and as appropriate internal or 
external reference; result (indicate the signals corresponding to the solvent and the 
impurities). 
d) Mass Spectrum 
The identity of the substance; accelerating voltage; method of loading (direct insertion 
via GC, etc); mode (Electron Impact, Chemical Ionisation, Field Desorption, etc); 
molecular ion (M); significant fragments (i.e. especially those at higher mass); M/Z 
values or assignments. 
e) Gel permeation chromatography (only for polymers) 
The identity of the substance; solvent; temperature; characteristic values of the standards 
and columns; separation efficiency. 
f) Other spectra 
1.3.61 Chromatography 
Do not complete. Method should be given at section 1.4 and an HPLC etc. trace included in the 
analytical report. 
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1.4.00  METHODS OF DETECTION AND DETERMINATION 
A brief description of the methods used to support the information given under section 
1.3.10/1.3.30, or the appropriate bibliographical references, should be given. The description 
and/or the appropriate bibliographical references should be sufficient to allow a competent 
analytical chemist to repeat the measurements without further aid (e.g. for gas chromatography, 
give column dimensions and construction, packing material including support, any special 
treatments given, temperature used, internal standard if applicable, detectors, etc. where spectra 
have been used, simply refer to the details under section 1.3.50. 
 
1.5.00  COMPOSITION ON THE TESTED SUBSTANCE 
Give the exact composition of the samples, and the corresponding batch numbers, which were 
used to perform the tests in the sections 3.0.1 to 5.6.00 (the purity etc. must be within the ranges 
given in sections 1.3.10-1.3.40). 
It is much preferred that all tests are conducted on the same batch and, if so, this should be 
clearly indicated under this section. 
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SECTION A2 INFORMATION ON THE SUBSTANCE  
 
2.0.00  INFORMATION ON THE SUBSTANCE 
2.0.10 Technological process(es) used in production 
Only applies to sites in the EEA. A brief description of all technological process(es) used in 
production including specification of the system in which the notified substance will be produced 
(open/closed, continuous/batchwise), duration and frequency of production, maximum capacity 
per time-unit, pressure and temperature during processing, solvents used, production efficiency. 
2.0.20 Exposure estimates related to production 
Only applies to sites in the EEA. A brief description of the estimated exposure on the workplace, 
indirect to humans and to the environment, related to production. Numerical data are preferred. 
Working environment 
The most relevant moments of exposure should be described, for instance during filling, 
weighing, cleaning activities, sampling for quality and process control, in case of irregularities, 
etc. The estimated exposure in the workplace should be specified to the possible moments of 
exposure. if available, details concerning number of workers involved, level, route and duration 
of exposure should be provided for both during the working period and averaged over a longer 
period during working life. 
Indirect exposure to humans 
 
Environment 
Information on process water consumption; (pre)treatment of waste water and/or flue gas; 
capacity and function of the waste water treatment plant; emission in kg/day to air; quantity of 
and concentration in produced chemical waste 
2.0.30  Production sites (if available) 
Give the information of the production location(s) only for those manufacturers sited in the EEA. 
 
2.1.00  PROPOSED USES 
2.1.10 Types of use; Use category 
Indicate the general use category in coded or in non-coded form e.g. dyestuff, solvent, stabilizer 
(see the technical guidance for risk assessment or annexes 2 and 4 of this guidance for the use 
codes). 
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2.1.20 Desired effects 
The main purpose(s) for which the substance is to be supplied should be given in coded form, 
e.g. colouring agent, solvent (see the technical guidance for risk assessment or annexes 3 and 4 
of this guidance for the codes for desired effects). 
2.1.30 Detailed information on envisaged uses: 
Indicate in detail what effect is required e.g. imparting of brilliant fixed colour, medium for 
carrying active ingredients; U.V. light stabilizer in paints. Full content range should be given 
(e.g. 5-60%) for preparations(s) etc. and in final products. 
Provide the following information (2.1.35) on paper, as it is not present in the SNIF proforma. 
2.1.35 Statement, with relevant information, if the polymer has been developed 
to be environmentally degradable. 
Give a statement, with relevant information, if the polymer has been developed to be 
environmentally degradable. Detailed information on test method and result should be given 
under section 5.2.00. 
2.1.40  Form under which the substance is marketed 
Give the information under which form the substance is placed on the market (for example as a 
preparation/product/substance as such). 
If the substance is placed on the market as a preparation or product  
• Trade name(s) of the preparation(s) and/or product(s) 
• Form (e.g. granulate, paste, solution etc.) 
• The maximum content and/or range in percentages of the substance in the 
preparation(s) and/or product(s). 
2.1.50 Technological process(es) related to the use of the substance 
A brief description of all technological process(es) related to the use of the substance or 
preparation including specification of the system in which the substance will be processed 
(open/closed, continuous/batchwise), duration and frequency of processing, maximum capacity 
per time-unit, pressure and temperature during processing, solvents used, processing efficiency. 
Justify if the information is not available. 
2.1.60  Exposure estimate(s) related to use 
Give the information of the estimated exposure related to the use of the substance, in the 
workplace, to consumers, indirect to humans and to the environment. Numerical data are 
preferred. 
Justify if the information is not available. 
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Workplace environment 
The most relevant moments of exposure should be described, for instance during filling, 
weighing, cleaning activities, sampling for quality and process control, in case of irregularities, 
etc. The estimated exposure on the workplace should be given for all routes of exposure and be 
specified to the possible moments of exposure. If available, details concerning number of 
workers involved, level, route and duration and frequency of exposure should be provided for 
both during the working period and averaged over a longer period during working life. Also, the 
likely pattern of control should be provided. 
Indirect exposure to humans 
 
Environment 
Information on process water consumption; (pre)treatment of waste water and/or flue gas; 
capacity and function of the waste water treatment plant; emission in kg/day to air; quantity of 
and concentration in produced chemical waste. 
2.1.70  Fields of application with approximative breakdown 
Give information on who (industry, Skilled Trades, or Public) will use the substance or 
preparation and in what proportions, e.g. industry, open systems, 60%; public at large, open 
systems, 40%. 
Note: although a closed system is possible, under current guidelines the substance must be totally 
confined with no detectable release to the environment or exposure of workers under normal 
operating conditions, to justify such an entry. In practise some release might be expected during 
sampling, cleaning activities, weighing and in case of irregularities, during processing. 
2.1.80 Identify of recipients 
Give Name, Address, etc. of the recipient(s) of the substance or preparation. Do not complete if 
part of the legal entity of the notifier. Justify if the information is not available. 
2.1.90 Waste quantities and composition of waste resulting from the proposed 
uses 
Estimates or actual values of the waste quantities and composition of the waste resulting from 
the proposed uses should be provided where available. Justify if the information is not available. 
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2.2.00 ESTIMATED PRODUCTION IN AND/OR IMPORTS INTO THE EEA 
FOR EACH USE AND FOR EACH FIELD OF APPLICATION 
2.2.01  Production and/or Imports 
Indicate whether the substance will be produced in the EEA and/or imported from outside the 
EEA 
2.2.01/02 Balance of the production and/or imports for the calendar year and the 
calendar years thereafter 
Give the estimated production/imports in tonnes (a) for the remainder of the calendar year of 
notification and (b) for each calendar year thereafter (minimum of 3 years). 
Note: if in the event the quantity is markedly different, the Competent Authority must be 
informed - as it should be for substances notified according to Annex VII A if the total tonnage 
supplied to the EEA exceeds 10, 100 or 1000 tonnes per calendar or cumulative totals of 50, 500, 
or 5000 tonnes year. A proposal for a material safety data sheet should be provided in the case 
that the notified substance should be classified and labelled. Ranges should be avoided if 
possible. 
2.2.03 Estimated imports in case of sole representative. 
Give the estimated production/imports in tonnes (a) for the remainder of the calendar year of 
notification and (b) for each calendar year thereafter (minimum of 3 years). In the case of more 
than 1 manufacturer the importers should be linked to his manufacturer. 
2.2.10  Production and/or Imports Broken Down (in accordance with 2.1.10, 
2.1.20, and 2.1.70) 
For example: During first year 
 1) as a solvent Industry; open,  80% 
  Public at large; open,  10% 
 2) as a feedstock Industry; open,  10% 
 
2.3.00  RECOMMENDED METHODS AND PRECAUTIONS 
For the recommended methods and precautions one has to consider the technological process, 
the exposure during use given by the types of use and the fields of application - as indicated 
under sections 2.1.10 and 2.1.20 - and all dangerous properties of the substance. In the case of 
several technological processes and several types of uses the recommended methods and 
precautions must be specified. The proposed precautions must be provided in concrete terms and 
should result in an effective protection of the exposed population and the environment. Only 
mentioning general recommendations, like prevent skin contact, does not satisfy. In addition, 
some substances which are not formally classified as dangerous following base-set testing (for 
example those with positive results in in-vitro short term tests for mutagenic or carcinogenic 
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properties, or where structure activity relationships (SAR) suggests potential to produce effects, 
such as respiratory sensitisation, not investigated at the base-set), may nevertheless still need to 
be treated as dangerous. For other not formally classified substances the provided information 
must specify methods and precautions to prevent excessive exposure. The information provided 
in this section should be consistent with the information in the material safety data sheet. 
2.3.10  Handling 
Engineering controls, in particular methods of controlling exposure at source, are preferable and 
should be described or referred to, e.g. available national codes of practice. These might be by 
total enclosure of the substance, partial enclosure and extraction equipment, or adequate general 
ventilation, as appropriate; also by the institution of safe systems of work/handling. Personal 
protective equipment should be advised only when other measures cannot adequately control 
exposure. Where personal protective equipment and clothing is advised, full specifications 
should be given (e.g. the type of dust mask required, referring to appropriate international 
standards; the design and composition of gloves etc.) Appropriate precautions should be given 
for substances which are flammable, oxidising, etc. (e.g. avoid sparks, naked flames; keep away 
from combustible material). Besides engineering controls and personal protective equipment, 
hygienic or organisational measures (e.g. administrative control) should be described. 
2.3.20  Recommendations for proper storage 
Considering the relevant dangerous properties, recommendations for safe storage should be 
given (e.g. ventilation system for the store rooms, type of container, conditions for storage, 
regulations for not storing the substance together with other substances, any necessary 
temperature regime). 
2.3.30  Recommendations for transport 
These should include the recommendations to enable safe movement of the substance within a 
factory to avoid hazards for workers. Of particular importance are the use of sufficiently resistant 
containers, movement in closed containers and measures to avoid the crushing of containers due 
to a fall during movement. 
In addition, where international transport codes are known, these should also be specified, e.g. 
UN, IATA, EEC. 
2.3.40 Fire hazards, (recommendation for appropriate extinguishing agents and 
nature of the products of combustion or pyrolysis) 
Specify the nature of the combustion products (e.g. NOX) are likely to arise during a fire 
(indicate if a test result) and indicate suitable extinguishing agents and personal protective 
equipment. If pyrolysis is likely during use or disposal, the reaction products, with their chemical 
compositions, should be given where these are known. 
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2.3.50 Other dangers, particularly reaction with water 
In addition to dangers due to the substance, indicate whether it reacts with water to give, for 
example, toxic, explosive or flammable gases. Other dangers could be polymerisation reactions 
resulting in a large increase in volume, possibility of dust explosions, strongly exothermic 
reactions, possible respiratory sensitisation from a reactive dye, etc. 
2.3.60 Dust explosion 
Information on dust explosivity of the substance should be given. Test results should be given in 
section 3.1.40. If dust explosivity is likely precautions must be provided. 
 
2.4.00 EMERGENCY MEASURES IN THE CASE OF ACCIDENTAL 
SPILLAGE 
Give information on the appropriate measures for protection of man and the environment in the 
case of accidental spillage; e.g. "isolate the spillage", "evacuate personnel from the immediate 
vicinity", "absorb using inert material", "do not discharge to waste water system", etc. 
 
2.5.00 EMERGENCY MEASURES IN THE CASE OF INJURY TO PERSONS 
The information given here is intended for the purpose of immediate first-aid treatment. It is not 
intended to replace definitive diagnosis and treatment which can only be undertaken by a 
qualified doctor (specify to eyes, skin, ingestion and inhalation). 
 
2.6.00 PACKAGING OF THE SUBSTANCE AND/OR PREPARATION 
Give information how the substance/preparation should be packaged and transported; brief 
details of packaging for the various quantities and the type of container including material used 
for its construction (e.g. "polyethylene-lined 20 litre steel drums") should be given. 
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SECTION A3 PHYSICO-CHEMICAL PROPERTIES 
Note: Where the relevant Annex V method provides for a number of possible alternatives, the 
specific procedure used should be identified in the "Methods" section. 
 
3.0.00  NATURE OF THE SUBSTANCE 
Give information on colour, physical state at 20°C and 101.3 kPa and the state (powder, 
crystalline, compact, viscous, etc.) of the substance. 
Particle Size: where the substance is a powder, information on "aerodynamic" particle size 
distribution and the details of the test procedure should be given in section 3.1.50 and not in this 
section. 
3.0.10  Melting Temperature/Freezing Temperature 
Applies to solids and liquids with a melting point above 0°C Measurements should be taken up to 
360°C or to decomposition if this occurs at a lower temperature. If decomposition occurs, the 
temperature of decomposition should be stated. For liquids the freezing temperature should be 
determined if above -20°C otherwise an indication from preliminary tests should be given. For 
viscous liquids, the 'Pour point' may be an acceptable alternative. 
3.0.20  Boiling Temperature 
Presumed to be measured at normal atmospheric pressure unless stated otherwise. Not applicable 
to gases or solids which either melt above 360°C or decompose before boiling (in which event 
give an estimate based on the result of section 3.4 or measure the boiling point under reduced 
pressure). If the substance does decompose before boiling, the temperature of decomposition 
should be stated. 
3.0.30  Relative Density 
Any variation from D20/14 should be explained. Test report should include all weightings and 
calculations used to obtain the result. 
3.0.40  Vapour Pressure 
Vapour pressure is a key value for the estimation of exposure. Any volatile impurities should be 
first removed. A log p versus 1/T curve should be constructed with at least two values quoted in 
the 0-55°C range and an estimate given for 20 or 25°C. There is no need to measure if 
calculations indicate that the value is probably < 10-5 Pa at 25°C. If a transition (change of state, 
decomposition) is observed, the following information should be noted: nature of the change, 
temperature at which the change occurs at atmospheric pressure, vapour pressure at 10 and 20°C 
above this temperature (unless the transition is from solid to gas). Although this parameter is 
more closely linked to section 3.0.20 than section 3.0.10, where a boiling point cannot be quoted 
due to decomposition and the melting point is above 360°C there is no need to attempt test 
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3.0.40; and for a melting point of < 360°C but > 200°C a limit value based on measurement or a 
recognised calculation method suffices. 
3.0.50  Surface Tension (of aqueous solutions) 
To be measured at or near 20°C using a solution of sufficient concentration such that any 
surface-activity potential is expressed; e.g. at 90% of saturation (quote concentration), to a 
maximum concentration of 1 g/l (where viscosity permits). If fairly soluble and surface-active, a 
measurement at a lower concentration should also be made. May be omitted where water 
solubility is very low, i.e. less than 1 mg/l. 
3.0.60 Water Solubility 
This should be determined at or near 20°C. If solubility/temperature dependence > 3% per °C 
then further measurements should be made at 10°C above and below the initially chosen 
temperature. The full test report should include calibration data required for the chosen analytical 
method and the readings for the test solutions. If the substance appears "insoluble" in water, the 
detection limit of the analytical method should be indicated. 
3.0.70 Fat Solubility 
The determination of fat solubility is not required any more at or below base set, but may be 
requested at higher levels of supply. The fat solubility should be measured at 37°C. Any 
reasonably stable liquid at 37°C triglyceride may be used. The fatty acid composition and other 
essential details of the fat/solvent used should be given in the full test report as should calibration 
data for the chosen analytical method and the readings for test solutions. If suspected on 
structural grounds or from initial tests that the substance will be "miscible in all portions", this 
should be checked by running tests at 37°C with substance concentrations of 5, 50 and 95%. 
3.0.80  Partition Coefficient N-Octanol/Water 
Even for those substances which are extremely soluble/insoluble in the two phases, an attempt 
should be made to provide a limit value (if necessary based on the individual solubilities in n-
octanol and water). It is recognized that for surface-active substances, the measured result may 
only be approximate. The full test report should include calibration data required for the chosen 
analytical method(s) and the readings for test solutions. If the test cannot be performed, or it is 
impractical to do so, a calculated value for log P should be provided; details of the calculation 
method should be provided under "Method". Preferred methods are the Hansch and Leo method 
(see C. Hansch, A.J. Leo in Substituent Constants for Correlation Analysis in Chemistry and 
Biology, John Wiley, New York, 1979, and W. L. Lyman, W. F. Reehi, D. H. Rosenblatt (ed), 
Handbook of Chemical Property Estimation Methods, McGraw-Hill, New York, 1983) and the 
Rekker method (see R.F. Rekker, The hydrophobic gragmental constant, pharmacochemistry 
library, Elsevier, New York, 1977). 
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3.0.90 Flash Point 
The closed cup method is the only acceptable procedure. This method is mainly applicable to 
liquids and (if knowledge of the flash point is necessary for safe handling), also to waxy or pasty 
substances and low melting point solids. If an open cup method has been used and the flash point 
is above 70°C it may be acceptable. In such circumstances, contact the Competent Authority. 
 
3.1.00 FLAMMABILITY 
This section covers a number of properties which are determined by a number of different test 
methods in Annex V; the relevant test methods should be given in the summary dossier. If any 
test is omitted (e.g. A12/A13) justification should be provided under "Comments" to the effect 
that experience indicates that either the result is expected to be negative, or that the substance 
will react violently under the conditions of the test. 
3.1.10 Explosivity 
These tests need not be carried out when available thermodynamic information (heat of 
formation, heat of decomposition) or absence of certain reactive groups in the structural formula 
(cf. Brethrick, Handbook of Reactive Chemical Hazards, Butterworths, London, 1979) or its 
"oxygen balance" (as indicated in the Institution of Chemical Engineers Booklet, 1957) 
establishes beyond reasonable doubt that the substance is incapable of decomposing, forming 
gases or releasing heat very rapidly. 
3.1.20 Self Ignition Temperature (Auto-Flammability) 
The test is not applicable to explosive compounds; and when carried out on a solid, the test 
(A16) is terminated at the melting point. Test A15 should be performed on waxy or pasty 
substances or very low melting point solids (<50°C) For substances with a low melting point 
(<l00°C) the advice of the Competent Authority should be sought. Test A15 should not be 
carried out when A16 gave a positive result. For test A15, the method used must be given under 
"Method". 
3.1.30 Oxidizing Properties 
This test is not applicable to liquids and gases, explosive or highly flammable substances, 
organic peroxides or to combustible solid substances liable to melt under the conditions of the 
test. In addition, the test is not applicable if it can be demonstrated, for example on the basis of 
the chemical structure, that the substance is incapable of reacting exothermically with 
combustible materials. With cellulose as the combustible substance, false positives may occur if 
the test substance shows increased flammability rather than oxidizing properties. The test should 
be repeated using an inert substance, such as kieselguhr, and/or with cellulose in an inert 
atmosphere. Detailed guidance is available from the Competent Authority. 
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3.1.40  Additional Physico-Chemical Properties 
Details of additional tests, e.g. viscosity, stability tests, dust explosion tests etc. should be 
included here. 
3.1.50  Particle Size 
In case the substance is a powder, a particle distribution measurement should be provided. A full 
test is not required if no particles less than 100 microns are present. 
3.1.60  More Physico-Chemical Tests 
General: 
Additional tests especially required for polymers. 
Test 1. Molecular weight distribution 
 2. Thermal weight distribution 
 3. Extractivity 
Water solubility of polymers. See item 3.0.60. 
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SECTION A4 TOXICOLOGICAL STUDIES  
 
4.1.00  ACUTE TOXICITY 
General 
Substances other than gases should be tested by oral administration (4.1.10) and either by the 
dermal or inhalation route dependent upon the nature of the substance and the likely route of 
human exposure. In the case of fine powders. (see 3.1.50: there is as yet no agreed rule linking 
that result to a presumptive use of the inhalation route, but one current suggestion is that the 
presence of >10 % of particles <10 microns MMAD should be considered strongly indicative), 
consideration should be given to testing by the inhalation route. Gases should be tested by the 
inhalation route alone. Volatile liquids should be tested by the oral and inhalation routes. The 
notifier should include a justification for the choice of the second exposure route in the 
'Comments' section. The technical guidance documents related to the risk assessment Directive 
93/67/EEC provide criteria for the selection of the relevant exposure route. 
4.1.10 Administered orally 
4.1.11  Complete LD50 toxicity procedure 
Classification Indicate how/if classified as a result of this test; enter 'T+' (very toxic), 'T'  
(toxic), 'Xn' (harmful), or NC' (Not Classified) only. 
Limit test Single character entry. Indicate Y(es) or N(o) 
LD50 One value should be given. If both sexes are tested at each dose level, 
then the combined LD50 should be stated. Where there is a significant 
difference in response between the sexes (i.e. greater than two-fold) this 
should be reported in the "Comments" section. If the LD50 is determined 
on only one sex with a confirmatory study on the other sex at only one 
dose level, the LD50 value is stated here and information on the result of 
the confirmatory study is given in the "Comments" section. 
95% Confidence Give the confidence limits of the reported LD50 limits 
Slope of dose Express the slope in probit units per log10 dose mortality curve 
Species/strain Specify the species/strain of the test animal, e.g. Wistar (SPF) rat, 
Sprague Dawley rat. The rat is the preferred species. 
Vehicle Give its composition before test substance is added e.g. 2% aqueous-
carboxymethyl cellulose, propylene glycol. Indicate whether the test 
substance is in solution or suspension. 
Results Deaths to be given in the form of a table showing sex/dose given/no of 
animals/no of deaths should be those considered to be due to the test 
substance. Information on any other deaths should be given briefly under 
"Comments". 
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Sex Dose (mg/kg) This is a Table, structured for entry of one text character (Sex), and three 
Number of animals numeric entries. Unit (mg/kg) for the numeric entry for the dose is pre-
Number of deaths defined in SNIF, therefore enter only numeric values in these fields. 
A typical entry might be as follows: 
M 2000 5 0 
F 2000 5  0 
Signs of toxicity The signs listed should only be those considered to be due to the test 
substance. They should be related to dose level, time of onset and 
duration. It may be appropriate to indicate the time of deaths, especially 
if they are delayed. If animals appear to recover completely, appropriate 
details should be given. If it is considered there were no substance-
related signs of toxicity, this is stated. 
Effects in organs The effects listed should only be those considered to be due to the test 
substance and indicate their relationship to dose level. If a difference in 
effects is observed between animals that died/were killed in extremis 
during the study and those killed at termination, then note separately. If it 
is considered that there were no substance related effects on organs, this 
should be stated. 
Method e.g. 87/302/EEC, B1 (Acute oral toxicity) 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
Comments It is sometimes pertinent to state whether the highest concentration tested 
was the maximum attainable. 
4.1.12  Fixed-dose toxicity procedure 
Classification indicate how/if classified as a result of this test; enter 'T+' (very toxic), 'T' 
(toxic), 'Xn' (harmful), or 'NC' (Not Classified) only. 
Discriminating dose Which of the 4 fixed doses is indicated (5, 50, 500 or 2000 mg/kg bw). 
Preliminary sighting 
study 
Number of animals Give the number of males and female in the preliminary sighting study. 
Species/strain Specify the species/strain of the test animal, e.g. Wistar (SPF) rat, 
Sprague Dawley rat. The rat is the preferred species. 
Results Evidence of toxicity and mortality should be summarised in a table 
showing the fixed doses administered; enter 'Y' (Yes) or 'N' (No) only. 
Additional doses not shown already in the table should be added. 
Observations Enter any effects observed in the preliminary study. 
Main study 
Number of animals Give the number of males and female in the main study 
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Species/strain Specify the species/strain of the test animal. The rat is the preferred 
species. 
Vehicle Give its composition before test substance is added e.g. 2% aqueous-
carboxymethyl cellulose, or write 'None'. Indicate whether the test 
substance is in solution or suspension. 
Results of the Evidence of toxicity and mortality should be summarised in a table  
initial(I) and  showing sex/the fixed doses specified in the 92/69/EEC test method (i.e.  
further(F) dosing  5, 50, 500 and 2000 mg/kg)/number of animals/number of deaths. Dose  
 levels other than those specified are not acceptable in the main study. 
Observations Include any notable observations that cannot be entered in the section 
below. 
Signs of toxicity The signs listed should only be those considered to be due to the test 
substance. They should be related to dose level, time of onset and 
duration. It may be appropriate to indicate the time of deaths, especially 
if they are delayed. If animals appear to recover completely, appropriate 
details should be given. If it is considered there were no substance-
related signs of toxicity, this is stated. 
Effects in organs The effects listed should only be those considered to be due to the test 
substance and indicate their relationship to dose level. If it is considered 
that there were no substance related effects on organs, this should be 
stated. 
Method e.g. 92/69/EEC, Bl.bis (Acute oral toxicity - Fixed Dose Procedure) 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
Comments It is sometimes pertinent to state whether the highest concentration tested 
was the maximum attainable. 
4.1.20  Administered by Inhalation 
Classification Indicate how/if classified as a result of this test; enter 'T+' (very toxic), 'T' 
(toxic), 'Xn' (harmful), or 'NC' (Not Classified) only. 
Limit test Single character entry. Indicate Y(es) or N(o) 
LD50 One value should be given. If both sexes are tested at each dose level, 
then the combined LD50 should be stated. Where there is a significant 
difference in response between the sexes (i.e. greater than two-fold) this 
should be reported in the "Comments" section. If the LD50 Is determined 
on only one sex with a confirmatory study on the other sex at only one 
dose level, the LD50 value is stated here and information on the result of 
the confirmatory study is given in the "Comments" section. 
95% Confidence Give the confidence limits of the reported LD 
limits 
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Slope of dose Express the slope in probit units per log10 dose 
mortality curve 
Species/strain Specify the species/strain of the test animal, e.g. Wistar (SPF) rat, 
Sprague Dawley rat. The rat is the preferred species. 
Exposure period Enter the daily exposure period as an integer 
(hours) 
Method of exposure This would be 'whole body', 'oro-nasal', or 'head only'. 
Physical form Enter 'S' (solid), 'L' (liquid), or 'G' (gas) only. 
Mass median aero- The MMAD of particles to which animals were exposed is stated. In  
dynamic diameter addition, some indication of the range of particle sizes should be given,  
(for liquid and e.g. 2.2µ, or 75% of particles < 5µ. 
solid aerosols) 
Vehicle Give its composition before test substance is added e.g. 2% aqueous-
carboxymethyl cellulose, propylene glycol. Indicate whether the test 
substance is in solution or suspension. 
Results Deaths to be given in the form of a table showing sex/dose given/no of 
animals/no of deaths should be those considered to be due to the test 
substance. Information on any other deaths should be given briefly under 
"Comments". 
Sex Conc (mg/l) This is a Table, structured for entry of one text character (Sex), and 
Number of animals three numeric entries. Unit (mg/l) for the numeric entry for the  
Number of deaths concentration is pre-defined in SNIF, therefore enter only numeric values
 in these fields. A typical entry might be as follows: 
M 5.10 5  0 
F 5.10 5 0 
Signs of toxicity The signs listed should only be those considered to be due to the test 
substance. They should be related to dose level, time of onset and 
duration. It may be appropriate to indicate the time of deaths, especially 
if they are delayed. If animals appear to recover completely, appropriate 
details should be given. If it is considered there were no substance-
related signs of toxicity, this is stated. 
Effects in organs The effects listed should only be those considered to be due to the test 
substance and indicate their relationship to dose level. If a difference in 
effects is observed between animals that died/were killed in extremis 
during the study and those killed at termination, then note separately. If it 
is considered that there were no substance related effects on organs, this 
should be stated. 
Method e.g. 87/302/EEC, B2 (Acute inhalation toxicity) 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
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Comments It is sometimes pertinent to state whether the highest concentration tested 
was the maximum attainable. 
4.1.30 Administered Cutaneously 
Classification Indicate how/if classified as a result of this test; enter 'T+' (very toxic), 'T' 
(toxic), 'Xn' (harmful), or 'NC' (Not Classified) only. 
Limit test Single character entry. Indicate Y(es) or N(o) 
LD50 One value should be given. If both sexes are tested at each dose level, 
then the combined LD50 should be stated. Where there is a significant 
difference in response between the sexes (i.e. greater than two-fold) this 
should be reported in the "Comments" section. If the LD50 Is determined 
on only one sex with a confirmatory study on the other sex at only one 
dose level, the LD50 value is stated here and information on the result of 
the confirmatory study is given in the "Comments" section. 
95% Confidence Give the confidence limits of the reported LD50 
limits 
Slope of dose Express the slope in probit units per log10 dose 
mortality curve 
Species/strain Specify the species/strain of the test animal, e.g. Wistar (SPF) rat, 
Sprague Dawley rat. The rat is the preferred species. 
Exposure period Enter the daily exposure period as an integer, e.g. 24 (hours) 
(hours) 
Type of dressing Enter 'O' (Occlusive) or 'S' (Semi-occlusive) 
Vehicle Solids should only be moistened with e.g. water or corn oil. Liquids are 
generally tested undiluted. 
Results Deaths to be given in the form of a table showing sex/dose given/no of 
animals/no of deaths should be those considered to be due to the test 
substance. Information on any other deaths should be given briefly under 
"Comments". 
Sex Dose (mg/kg) This is a Table, structured for entry of one text character (Sex), and 
Number of animals three numeric entries. Unit (mg/kg) for the numeric entry for the dose 
Number of deaths is pre-defined in SNIF, therefore enter only numeric values in these
 fields. A typical entry might be as follows 
M 2000 5 0 
F 2000 5 0 
Signs of toxicity The signs listed should only be those considered to be due to the test 
substance. They should be related to dose level, time of onset and 
duration. It may be appropriate to indicate the time of deaths, especially 
if they are delayed. If animals appear to recover completely, appropriate 
details should be given. If it is considered there were no substance-
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related signs of toxicity, this is stated. Effects at the site of application 
(local) and systemic effects are distinguished. 
Method e.g. 92/69/EEC, B3 (Acute inhalation dermal) 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
Comments it is sometimes pertinent to state whether the highest concentration tested 
was the maximum attainable. 
4.1.50 Skin Irritation 
General 
This test should not be conducted with strongly acidic or alkaline substances (see current OECD 
test guidelines). The testing of substances which have been shown to be very toxic by the dermal 
route may be unnecessary. 
In some studies the test substance will have been applied to both intact and abraded skin; the 
latter procedure is additional to Annex V guidelines and is not used for classification and 
labelling purposes. If it is considered necessary to report results for abraded skin it is essential 
that this cannot lead to confusion, and results from abraded skin should be described in the 
section "Other observations" and clearly indicated as relating to abraded skin. 
Classification Indicate how/if classified as a result of this test; enter 'C' (Corrosive), 'Xi' 
(Irritant), or 'NC' (Not Classified) only. 
Species/strain Specify the species/strain of the test animal. The rabbit is the preferred 
species, e.g. rabbit NZW (New Zealand White). 
Number of animals Give the number of animals tested. 
Duration of  Give the duration of exposure in hours. 
exposure 
Amount of  Give the amount in mg. 
substance 
Type of dressing Enter 'O' (Occlusive) or 'S' (Semi-occlusive) only. 
Vehicle Give its nature and composition, e.g. moistened with water 
Reversibility of any In interpreting the results it is essential to have information on the 
observes effects reversibility of the observed effects. Therefore, notifiers are required to
 indicate whether the effects were fully reversible and, if so, within what 
 time period. If the effects were not fully reversible, the length of the 
 observation period must be stated (if less than 14 days, justification must 
 be provided under "Comments"). In addition, maximum scores at the end
 of the observation period should be stated in the table of "Overall results" 
 (see below). 
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Overall results The overall results should be given in the form of a table. The scores 
refer to intact skin only. 
If 3 animals or less were used, mean scores for each animal are given for 
each end-point (erythema/eschar and oedema). If more than 3 animals 
were used, one overall mean score is given for each end-point. 
The mean scores are calculated as indicated in Commission Directive 
93/21/EEC. The "maximum value" is defined as the maximum individual 
score for any animal during the whole observation period (not limited to 
the 24-72 hour period). The "maximum duration of any effect" is defined 
as the longest period in days during which an irritant response (of any 
severity) was seen in an animal. The "maximum value at the end of the 
observation period" is the maximum score for each end-point in any 
animal at the end of the observation period. This information is only 
required if the effects were not fully reversible (see "Reversibility of any 
observed effects"). 
Other observations Erythema/eschar and oedema: sufficient details will often have been 
provided under "Overall results" but in some cases it may be appropriate 
to describe reactions seen before the 24 hour reading (or after the 72 hour 
reading). Details of other effects, especially of a serious nature, seen 
during the study should be given e.g. type of effect, severity, number of 
animals affected and duration. Where the test substance produces 
discolouration of the skin such that interpretation of the effects is made 
difficult, additional information e.g. histopathological or skin fold 
thickness should be given. If a study is terminated before the 72 hour 
reading because of severe skin irritation or corrosion, the "Overall 
results" entry cannot be completed and therefore full details must appear 
under this section including motivation for the scores and the proposed 
classification and labelling. 
Method e.g. 92/69/EEC, B4 (Acute toxicity - Skin irritation) 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
Comments Comments should be made on any aspects of the test which may 
influence the results. Comments should be full but concise 
4.1.60  Eye Irritation 
General 
Strongly acidic or alkaline substances and substances which have demonstrated define 
corrosivity or severe irritant properties in a dermal irritation study, or in other studies, should not 
be tested for eye irritation (see current OECD test guidelines). 
In some studies the effect of irrigating the eye following application of the test substance will 
have been investigated. However, normally only results from non-irrigated eyes are used for 
classification. If results from irrigated eyes are reported, they should be given under the section 
"Other observations" and should be clearly indicated as relating to irrigated eyes. 
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Classification Indicate how/if classified as a result of this test; enter 'C' (Corrosive), 'Xi' 
(Irritant), or 'NC' (Not Classified) only. 
Species/strain Specify the species/strain of the test animal. The rabbit is the preferred 
species, e.g. rabbit NZW (New Zealand White). 
Number of animals Give the number of animals tested. 
Nature of the The entry here would be for example: powder or undiluted liquid 
substance 
Amount of the The entry here would be for example: 0.1 g for powder or 0.1 ml for  
substance liquids or diluted solids. 
Reversibility of any See entry under section 4.1.50; however, for this test, justification must  
observed effects be provided under "Comments" if the observation period was less than 21
 days. 
Overall-results See entry under section 4.1.50. The values quoted apply to unirrigated 
eyes. 
Other observations Ocular lesions will have been described under "Overall results" but in 
some cases it may be appropriate to describe reactions seen before the 24 
hour reading (or after the 72 hour reading). Details of other effects, 
especially of a serious nature, seen during the study should be given e.g. 
type of effect (e.g. lacrimation, discharge), severity, number of animals 
affected and duration. If a study is terminated before the 72 hour reading 
because of severe eye irritation, the "Overall results" entry cannot be 
completed and therefore full details must appear under "Other 
observations" including motivation for the scores and the proposed 
classification and labelling. 
Method e.g. 92/69/EEC, B5 (Acute toxicity - Eye irritation) 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
Comments If the observed effects were such as to require the use of Risk Phrase 
R41, this should be stated. 
4.1.70 Skin Sensitisation 
General 
A test in the guinea-pig is required: if the substance can be applied intradermally, the 
Maximisation test is the highly preferred method. If it is not technically possible to conduct the 
Maximisation test and the Buehier test is used, the reason should be given. The intradermal and 
dermal induction concentration is adjusted to the level that produces evidence of skin irritation 
(score 112), but that is well tolerated by the animals in each induction stage. Where the test 
substance does not induce irritation, the test should be carried out with the highest concentration 
and with due provision for optimal skin penetration (pretreatment with 10% sodium lauryisulfate 
solution). The maximum induction concentration of 25% for solids used at first by Magnusson 
and Kligman cannot be considered as an absolute limit value (see also Kligman & Basketter, 
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1995, in Contact Dermatitis 32); liquids if appropriate should be applied directly. The choice of 
the vehicle should be justified. 
Classification Indicate how/if classified as a result of this test; enter 'Xi' (Irritant), or 
'NC' (Not Classified) only. 
Species/strain Specify the species/strain of the test animal. The guinea-pig is the 
required species, e.g. female albino Dunkin-Harley guinea pig 
Number of animals Give the number of animals tested. 
in test group 
Number of animals Give the number of animals in the control group. 
in negative control 
group 
Maximum conc. This should be addressed. 
not giving rise to 
irritant effects in 
preliminary test 
Conc. of test Give the intradermal and the dermal concentration of the test substance in 
material used at each induction 
induction 
Conc. of test Give the dermal concentration of the test substance in the challenge  
material used at  stage. 
challenge 
Signs of irritation This is important information as it can indicate whether a satisfactory  
during induction dose level was used for induction. 
Results In the main body of the table given for summarising the test results, the 
term "skin reaction" includes both irritation and/or sensitisation effects. 
Beneath the main table in the sub-section headed %umber of animals 
showing evidence of sensitization at each challenge concentration", the 
number of animals showing a true sensitization response should be 
stated. Ideally there should be no skin reactions in the negative control 
animals at challenge. In such a case the incidence of sensitisation is 
equivalent to the incidence of skin reaction in the test group. 
Interpretation can become difficult when skin reactions are seen in 
negative control animals. Data for all challenge concentrations and times 
should be provided. If a second challenge is performed the time interval 
between the first and second challenge should be stated under "Other 
observations". 
Method The type of test e.g. Buehier, Maximisation should be stated, e.g. 
92/89/EEG, B6 (Guinea Pig Maximization Test). Details should be 
provided if the method used differs from the standard method for a 
particular test, e.g. the use of only dermal application of the test 
substance in a Maximisation test. 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
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Comments A statement justifying the dose levels used for both induction and 
challenge should be made. It may be appropriate to comment on the basis 
for deciding whether skin reactions at challenge were evidence of 
sensitisation or irritation (e.g. comment on magnitude of skin responses 
seen). Any problems of interpreting test results arising from discoloration 
of the skin by the test substance should be identified. Where histological 
studies are used to differentiate between irritant and sensitising effects 
these should be described. 
 
4.2.00  SUBACUTE TOXICITY 
General 
Oral, inhalation and dermal route of application should be considered. The decision for a certain 
route depends on the proposed uses of the substance, the results of its acute toxicity tests and on 
its physico-chemical properties. The dermal route should be avoided if the substance obviously 
does not penetrate the skin, as indicated by water and fat solubility and by the results of the 
dermal acute toxicity test. Generally the preferred route is the oral one (see also the "General" 
comments at start of section 4.1.00). The choice of the route of administration must be justified. 
A report of a sub-acute toxicity study requires particularly careful and critical assessment. Only 
effects that are considered to be due to the test substance should appear in the summary 
document. The usefulness of a summary is increased greatly if responses are quantified (e.g. 
number of animals affected, magnitude/severity of effects, time of onset and duration) and any 
dose/concentration response is mentioned. Important effects should be described quantitatively 
as a deviation from the values seen in the control animals. Emphasis should be given to effects of 
toxicological significance, but it should also be indicated if effects were observed which were 
considered not to be of toxicological significance. Statistically significant differences occurring 
merely by chance should not be reported. If animals appear to recover completely, details should 
be provided, and results of any recovery-group experiment should be reported. If no signs of 
toxicity considered to be due to the test substance were seen this should be stated. 
4.2.10  Sub-Acute Toxicity 28/90 day-test 
The strategy for assessing the requirement for further repeated-dose studies at higher supply 
levels is described in the Technical Guidance. 
See for section 4.1.11 and in addition: 
Classification Indicate how/if classified as a result of this test; enter 'T' (Toxic), 'Xn' 
(Harmful), or 'NC' (Not Classified) only. 
Limit test (Y/N) Single character entry. Indicate Y(es) or N(o). 
Route of e.g. Oral, Dermal, or Inhalation, etc. In SNIF, only two characters are  
administration available for this entry, as follows: 
OR (oral)  DM (dermal)   IN (inhalation) 
IV (intra-venous) M (intra-muscular) JP (intra-peritoneal) 
SU (sub-cutaneous) 
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Dose or conc. This is the doses or concentration at which no substance-related  
at which no toxic toxicologically significant adverse effects were observed. It should be  
effects were noted that this dose level indicating the level at which "serious damage to  
observed health" is observed (i.e. the dose level at which R48 is applied) will
 usually be higher than at which "no effects" were observed. 
Mg/kg/day or, Enter value. 
m/1/…/h/day If not established, give '<' lowest dose used in the study. 
Species/strain Specify the species and (strain) of the test animal, e.g. Rat Wistar). The 
Rat is the preferred species. However data from studies using other 
species can be useful and should not be rejected. 
Method of Eg. gavage, diet, occlusive/semi-occlusive dressing, nose-only, etc. 
administration 
Vehicle The vehicle should be described clearly and in full (not abbreviated). 
Also, state whether the test substance is in solution or suspension. SNIF 
permits up to 60 characters for this entry. 
Mass median aero- The MMAD of particles to which animals were exposed is stated. In  
dynamic diameter addition, some indication of the range of particle sizes should be given,  
(for liquid and e.g. 2.2µ, or 75% of particles < 5µ. 
solid aerosols) 
Duration of Give the duration exposure in hours per day by inhalation or dermal. 
exposure per day Enter the daily exposure period as an integer 
Dosing regime 5 or 7 days/week. Enter '5' or '7' only. 
Number of animals The purpose of this summary table is to allow referral to group numbers  
doses, group number in the results section and hence facilitate presentation. Any recovery
 group should be identified and given group numbers different to the main
 test groups. Dose or concentration must be in mg/kg or mg/l. A typical
 entry might be the following: 
 Sex No. of Animals Dose or  
concentration 
1 M 5 0 
2 M 5 500 
3 M 5 1000 
1 F 5 0 
2 F 5 500 
3 F 5 1000 
 
Results Where appropriate, signs listed should be related to exposure level, time 
of onset and duration. If animals appear to recover completely, details 
should be provided and results of any recovery-group experiment should 
be reported. If no signs of toxicity were seen and considered to be due to 
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the test substance, this should be stated. Important effects should be 
described quantitatively, as a deviation from the values seen in the 
control animals. 
1. Clinical Free Text. Clear, concise and organised. 
observations Signs listed should only be those considered to be due to the test 
substance. Clinical observations include deaths, effects on body weight, 
food and water consumption, and any signs of ill-health, e.g. no deaths 
occurred and no sign of toxic effect observed; body weight gain slightly 
reduced in Groups 3, 4 and 6 during the period of dosing, but returned to 
control values by end of the recovery period in Group 6. 
2. Laboratory As 1) above, covering haematology, blood chemistry and urinalysis  
findings values e.g. No significant treatment-related changes to indicate a toxic
 effect. 
3. Effects in organs Summarise observations at necropsy (macroscopic) and at microscopic 
examination. It may be appropriate to distinguish effects seen in animals 
that died during the study from those in animals killed at termination. 
Results of interim or recovery animals should be reported. The effects 
listed should only be those considered to be due to the test substance, e.g. 
macroscopic effects, weight changes, microscopic effects, and are related 
to exposure level. Effects should be described quantitatively as a 
deviation from the control animals. 
Dose or conc. This is the dose or concentration at which no substance-related  
at which no effects toxicologically significant effects were observed. It should be noted that
 were observed this dose level would usually be lower than that at which
 "No toxic effect" (Serious damage to health) is observed. If not 
 established, give '<' lowest dose in this study. 
Method e.g. OECD 407 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
Comments Include here any information to explain the absence of entries to key 
fields above, or to clarify the interpretation of the study. If dosing was 
conducted in diet, or in drinking water, include calculated values, in 
mg/kg, for mean daily dosing. 
Comment on the no toxic effect level, or on observed principal effects: 
e.g. It is not possible to establish a reliable and unequivocal no toxic 
 effect level for this substance. 
 
e.g. As the effects observed at 100 and 1000 mg/kg were only minor, 
the dose at which no toxic effect occurred is considered to be 1000 
mg/kg. 
e.g. The primary target organ was the liver. The weights and pathology 
 of the other organs did not differ significantly from controls. 
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Note if a study is unacceptable, and why: 
e.g. The 90 day inhalation study was unacceptable because of severe 
and persistent intercurrent respiratory disease in all groups, 
including controls. 
Justification for the classification and labelling proposed (on the basis of 
the results of this test) may be necessary. 
4.3.00  MUTAGENICITY 
General 
At the base-set (Annex VII A) two mutagenicity tests are necessary, and at the reduced set 
(Annex VII B/C) only one mutagenicity test is necessary: one bacteriological for gene mutation 
(required at the reduced set) and one non-bacteriological for chromosomal aberrations. In order 
to maximise the detectability of any potential mutagenic hazard, and for the reason of animal 
welfare, the nonbacteriological test should be an in-vitro test. 
If after full and careful evaluation of the results of the test, it is not possible to conclude whether 
an overall result is definitely positive or definitely negative, that result has to be considered 
equivocal. In such a case, the equivocal response is recorded under "Observations" and 
"Comments" but neither "Result" box is ticked. 
In the event of a positive result in either test, further testing according to the strategy as described 
in the technical guidance documents for risk assessment for new substances should be carried 
out. 
For level 1 and level 2 the strategy for assessing the requirement for collecting further 
information to elucidate the mutagenic potential of a notified substance at higher supply levels is 
described in the Technical Guidance. 
The testing requirements at higher levels of supply are determined by considering at any stage in 
the life progress of a substance all information known to that point in relation to its mutagenic 
potential and intended use. 
4.3.10  Bacteriological Test 
These notes apply to Annex V, tests B. 13 and B. 14. 
Type of bacterial Salmonella typhimurium (e.g. TA1535, TA1537, TA1538, TA98,  
strain TA100) Escherichia coli. 
Conc. range Give the range of concentrations used in the main test with and without 
in the main test metabolical activation. 
Conc. producing Indicate which minimal concentration in the preliminary and in the main  
toxicity test both with and without metabolical activation shows toxic effects to 
 bacteria. 
Solvent Give the identity of the solvent. 
Conc. resulting in Concentration in microgram per plate. 
precipitation 
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Metabolic activation Enter the details of the metabolic activation used, e.g. Aroclor-induced 
system rat liver S9, or Phenobarbital/β-naphthoflavone-induced rat liver S9. 
Observations For equivocal or positive results some details of the response observed 
for named strains should be given, e.g. magnitude of the increase in 
revertants, plus any dose response. It should be stated whether results 
were confirmed in an independent experiment. 
Result It should be stated whether the overall result is considered to be negative 
or positive for both (a) experiments with metabolic activation and (b) 
experiments without metabolic activation. 
Method If, in order to make for a more informative test, the protocol differs from 
the Annex V bacteriological test, appropriate details should be provided, 
e.g. use of pre-incubation, use of a positive control that is structurally 
related to the test substance. 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by 
for test entering the appropriate code. 
Comments If an overall negative result has been obtained (either with or without 
activation) it is necessary to comment on the adequacy of the test, e.g. 
provide justification for the dose levels used and for the type of 
metabolising system in relation to the structure of the test compound, and 
to state whether positive controls gave a satisfactory response. 
4.3.20  Non-Bacteriological in vitro, 
General 
These notes apply to test B.10 which is designed to detect primarily structural chromosome 
aberrations. If effects on chromosome number (ploidy effects) have been investigated as well, 
additional information is required under "Observations" and "Result". 
Type of test Data collection for the tests listed below is achieved by using the 
same/similar proforma for all tests. Thus data-fields exist in the proforma 
to collect relevant information, but for any individual test some fields 
may be redundant. 
4.3.21 IN VITRO MAMMALIAN CYTOGENWY (B10) 
4.3.22 IN VITRO MAMMALIAN CELL GENE MUTATION (B17) 
4.3.23 UNSCHEDULED DNA SYNTHESIS - MAMMALIAN CELLS 
IN VITRO (B18) 
4.3.24 SISTER CHROMATID EXCHANGE ASSAY IN VITRO (B19) 
4.3.25 IN VITRO MAMMALIAN CELL TRANSFORMATION (B21) 
4.3.26 GENE MUTATION - SACCHAROMYCES CEREVISIAE (B15) 
4.3.27 MITOTIC RECOMBINATION - SACCHAROMYCES 
CEREVISIAE (B16) 
Type of cell used Describe, e.g. Chinese hamster V79 lung cells; mouse lymphoma 
L5178Y cells; rat hepatocytes; human lymphocytes; etc. 
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Conc. range Units (µg/ml) are assumed in SNIF, so enter only the numeric values. 
in the main test Enter the range of concentrations used in the main test, with and without  
(µg/ml) metabolic activation. Only a single line entry is allowed. Give the range
 tested in the first experiment, and provide details of the second 
 experiment in the 'Comments' section. 
Conc. producing Indicate which minimal concentration in both preliminary and main tests  
toxicity with and without metabolical activation shows toxic effects to bacteria.  
 A s inferred from e.g. the mitotic index; the degree of toxicity in both
 preliminary and main tests should be stated. 
with metabolic  e.g. 5-1000 
activation 
without metabolic  e.g. 5-1000 
activation 
Conc. producing Indicate which minimal concentration in both preliminary and main tests,  
toxicity with and without metabolic activation, shows toxic effects to the test 
 system. 
a) In a preliminary 
test 
with metabolic  e.g. >1000 
activation 
without metabolic  e.g. >1000 
activation 
b) In the main test 
with metabolic  e.g. >1000 
activation 
without metabolic  e.g. >50 
activation 
Vehicle The vehicle should be described clearly and in full (not abbreviated). 
Also, state whether the test substance is in solution or suspension. SNIF 
permits up to 60 characters for this entry. e.g. dimethyisuifoxide, arachis 
oil BP, distilled water. 
Exposure period This is the period of time, in hours, the cells are exposed to (incubated 
with) the test substance and should be completed for all test methods. 
The time-unit (hours) is pre-defined in SNIF. Enter numerical value only. 
Only a single numeric entry is permitted. Therefore, if more than one 
value is available, e.g. 20 and 44 hours, enter only the first value, and 
then enter all values in text in the 'Comments' section. 
with metabolic  e.g. 3 
activation 
without metabolic  e.g. 20 
activation 
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Expression time Free Text, or leave blank if not applicable. This applies to 4.3.22 and 
4.3.26. It relates to the period of time the cells are maintained in growth 
medium to allow induced mutations to be detected. Example values are, 
for the mouse lymphoma test, 3 days, and for the CHO mammalian cell 
gene mutation assay, 7 days. 
Selection time Free Text, or leave blank if not applicable. This applies to 4.3.22 and 
4.3.26. It relates to the period of time the cells are incubated with a 
selection agent, such as 6-thioguanine or trifluorothymidine, in order to 
determine the mutation frequency. 
Fixation time Free Text, or leave blank if not applicable. This equates to the harvest 
time. It is the period between the start of exposure to the test substance 
and the fixation or harvest of the cells. Values are required for 4.3.21, 
4.3.23 and 4.3.24. 
Metabolic activation Enter the details of the metabolic activation used, e.g. Aroclor-induced 
system rat liver S9, or Phenobarbital/β-naphthoflavone-induced rat liver S9. 
Observations In the case of tests with negative results, comment on the acceptability of 
control data. Also, comment on any precipitation observed. For equivocal 
or positive results, provide details of any response observed, e.g. type of 
structural damage, magnitude of effect, and any dose response. Similar 
information is required if ploidy effects have been investigated. In 4.3.23, 
indicate if large and small colonies were scored. Some example entries 
are given below: 
e.g. Reproducible increases (5.5-8.5% above the concurrent control 
values of 0-1 %) in the number of chromosomal aberrations 
(excluding gaps) occurred at 4000-5000 µg/mi (+S9). 
e.g. No significant or dose-related increases in the frequency of cells 
with aberrations were seen in either the first or second experiment. 
e.g. The positive control, cyclophosphamide, induced a significant and 
large increase in the frequency of aberrations. Negative control 
values were within the normal range. 
e.g. Responses obtained from the negative and positive controls 
demonstrated that the system was capable of detecting chemicals 
that caused chromosomal damage. 
Results Only a single character entry ('+', '-', or '0') is permitted:(if equivocal '0', 
tick 'see comments' box). In cases where '0' is entered (equivocal), further 
explanation should be provided in the 'Comments' section. If ploidy 
effects have also been investigated, the overall result for this end-point 
should also be stated in the 'Observations' section. 
with metabolic + 
activation (+/-) 
without metabolic - 
activation (+/-) 
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Method Clearly indicate the source of the test-method protocol, e.g. 87/302/EEC  
(type of test) or 92/69/EEC, OECD, or quoted publication, and the type of test, e.g.  
 (metaphase analysis), or (UDS-autoradiography). It is preferred that
 approved test methods are used, if possible. However, other methods may
 be used when necessary provided they are well validated and/or 
 scientifically justified. The choice of test-method should have been made
 by discussion with the Competent Authority, and scientific justification
 included in the test report.If a separate confirmatory study has been
 performed this should be reported in a separate entry (use function 'Add' 
 in the SNIF proformat). 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by 
for test entering the appropriate code. 
Comments Free Text. Include any additional information. If an overall negative 
result has been obtained (either with or without metabolic activation) or 
if there are data on the effect of the chemical on cell cycle time, it is 
necessary to comment on the adequacy of the test. 
Comment on any problems that make the result neither a clear positive 
nor a clear negative. 
In 4.3.25, 4.3.26 or 4.3.27, a brief description of the procedure should be 
included. 
Describe additional experiments not covered by previous entries (e.g. 
repeat experiments with additional exposure or fixation times). 
Give method and criteria for assessment of toxicity. This may include a 
significant reduction (50 %) in mitotic index, degree of confluency or 
cell counts, or a low relative cloning efficiency (<10 %). 
Justify any (apparently) unusual conditions as well as deviations from 
approved test 
In 4.3.21, two typical entries are as follows: 
a) Toxicity was observed as a decrease in mitotic index >50%. An 
additional fixation time of 48 hours was employed with S9. The 
concentration range in this test was 10-1000 µg/ml, and toxicity 
was observed at 700 µg/ml and above. 
b) The duration of the cell cycle of the CHO strain used is 12-13 
hours. The treatment and recovery periods therefore correspond to 
1.5 times a cell cycle (18 hours) and to 1.5 times a cell cycle plus 
24 hours (42 hours). 
4.3.30  Non-Bacteriological Test in vivo 
General 
These notes apply to Annex V tests B.11 (cytogenetics) and B.12 (micronucleus). The 
cytogenetics assay is designed to detect primarily structural chromosome aberrations. If effects 
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on chromosome number (ploidy effects) have been investigated as well, additional information is 
required under "Observations" and "Result". 
Type of test Data collection for the five tests listed below is achieved by using the 
same/similar proforma. Thus data-fields exist in the proforma to collect 
relevant information, but for any individual test some fields may be 
redundant. For other in vivo tests, individual proformas are provided and 
are illustrated later. 
4.3.31 IN VIVO MAMMALIAN BONE MARROW CYTOGENETICS 
(B1l) 
4.3.32 IN VIVO MAMMALIAN BONE. MARROW MICRONUCLEUS 
(B12) 
4.3.33 IN VIVO MAMMALIAN GERM-CELL CYTOGENETICS 
(B23) 
4.3.38 UNSCHEDULED DNA SYNTHESIS (IN VIVO/IN VITRO) 
4.3.39 In vivo mammalian bone marrow sister chromatid exchange (SCE) 
Species/strain Specify the species/strain of the test animal. 
Sex Dose (mg/kg) This is a Table, structured for entry of one text character (Sex), and 
Number of animals three numeric entries. Units (mg/kg and hours) for two of the numeric 
Sacrifice times entries are pre-defined in SNIF, therefore enter only numeric values in 
these fields. 
In 'Sacrifice times', there is a 'from - to' range. 
In 4.3.31 or 4.3.32, a typical entry might be as follows 
M 2000 5 24  48 
F 2000 5 24 48 
Doses producing For a cytogenetics assay, details of the effects on mitotic index should be 
toxicity given. For a micronucleus assay, details of the effect on the 
 polychromatic/normochromatic erythrocyte ratio should be given. In
 addition, for either assay, any evidence for a maximum tolerated dose 
 (e.g. death clinical signs of toxicity) should be stated. If no toxic effects
 were observed this should be stated. In fact, SNIF does not provide
 headings, but this information can be entered as required. 
i.e. Mitotic Index: e.g. >= 1000 µg/ml  
PIN Ratio: e.g. No effect seen 
Other toxic signs:  
- Give evidence for a maximum tolerated dose, indicate toxic 
endpoints, e.g. deaths, clinical signs, etc., or state that no signs of 
toxicity were reported/observed. 
Limit test Enter 'Y' (Yes) or 'N' (No) only. 
Route of e.g. Oral, Dermal, or Inhalation, etc. In SNIF, only two characters are 
administration available for this entry, as follows: 
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OR (oral)  DM (dermal)  IN (inhalation) 
IV (intra-venous) IM (intra-muscular) IP (intra-peritoneal) 
SU (sub-cutaneous) 
Vehicle The vehicle should be described clearly and in full (not abbreviated). 
Also, state whether the test substance is in solution or suspension. SNIF 
permits up to 60 characters for this entry. e.g. Distilled water; 0.5% 
aqueous carboxymethylcellulose. 
Observations Free Text. Describe positive effects. Indicate if statistical significance or 
dose-response observed. In the case of negative results, provide a 
summary to confirm that control data are adequate. For-equivocal or 
positive results some details of the response observed should be given: 
e.g. type of structural damage, magnitude of effect, plus any dose 
response. Similar information is required if ploidy effects have been 
investigated. 
Results Only a single character entry ('+', '-', or '0') is permitted: (if equivocal '0', 
tick 'see comments' box). In cases where '0' is entered (equivocal), further 
explanation should be provided in the 'Comments' section. If ploidy 
effects have also been investigated, the overall result for this end-point 
should also be stated in the 'Observations' section. 
with metabolic  + 
activation (+/-) 
without metabolic - 
activation (+/-) 
Method Clearly indicate the source of the test-method protocol, e.g. 87/302/EEC 
(type of test) or 92/69/EEC, OECD, or quoted publication, and the type of test, e.g.
 (Cytogenetics), (Micronucleus), (SCE), (UDS). It is preferred that 
 approved test methods are used, if possible. However, other methods may
 be used when necessary provided they are well-validated and/or 
 scientifically justified. Choice of test-method should have been made by
 discussion with the Competent Authority, and scientific justification 
 included in the test report. 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
Comments Free Text. Include any additional information here. If an overall negative 
result has been obtained it is necessary to comment on the adequacy of 
the test, e.g. provide justification for the dose levels used. In addition it 
should be remembered that a negative result in a bone marrow test in the 
absence of an effect on mitotic index or PIN ratio may occur due to 
failure of the test substance or its metabolites to reach the target tissue. In 
such a case the value of the result is limited. 
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4.3.34 Rodent Dominant Lethal 
Limit test (YIN) Single character entry. Indicate Y(es) or N(o) 
Details of the dose used should be entered into the 'Comments' section,  
e.g.5000 mg/kg (single administration) or 1000 mg/kg (repeated 
administration). 
Species/strain Specify the species and (strain) of the test animal. 
e.g. Rat (Wistar), Mouse (CD-1). 
Route of e.g. Oral, Dermal, or Inhalation, etc. In SNIF, only two characters are  
administration available for this entry, as follows: 
OR (oral) DM (dermal) IN (inhalation) 
IV (intra-venous) IM (intra-muscular) IP (intra-peritoneal) 
SU (sub-cutaneous) 
Method of  State if single or repeated administration, and frequency. 
Administration 
or of exposure 
Vehicle The vehicle should be described clearly and in full (not abbreviated). 
Also, state whether the test substance is in solution or suspension. SNIF 
permits up to 60 characters for this entry erg. Distilled water; 0.5% 
aqueous carboxymethylcellulose. 
Mass median Free Text. Enter the size range, e.g. 2.2µ, or 75% of particles < 5µ. 
aerodynamic 
diameter (for liquid  
an solid aerosols) 
Duration of Enter the daily exposure period as an integer  
exposure per day  
(inhalation or  
dermal) ... hours 
Dosing regime Enter '5' or '7' only. 
(5 or 7 days/week) Only a single numerical value is permissible here (5 or 7). If a single 
administration has been used, leave this field blank and enter details of 
the treatment in the 'Comments' section. 
Results Positive effects should be related to treatment and exposure level. If no 
sign of toxicity considered at 'tributable to the test substance is seen, this 
should be stated. Important effects should be described quantitatively as 
a deviation from the values seen in control animals. 
Sex Dose/conc. This is a Table, for Free Text entries. Unlimited number of lines 
(mg/kg), Number of permitted, e.g. 
animals, Group No  
M 0 5 1 
M 200 5 2 
M 800 5 3 
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Effects seen in males  Free Text. Describe any toxic effects observed during the period of the 
study. 
Number of Free Text Indicate pregnancy rate for each dose group in order to assess  
pregnancies affect of treatment 
Implantation effects Free Text Indicate pre- and post- implantation losses for each dose 
group. 
Overall result Free Text Indicate whether +ve or  -ve dominant lethal effect. 
Method e.g. 87/302/EEC, B.22 (Dominant Lethal Assay) 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
Comments Free Text Comment on the quality of the study. Describe the mating 
schedule. Refer to negative and positive control data. Include comments 
on the dosing regime. 
4.3.35 Mouse Spot Test 
Species/strain Specify the species and (strain) of the test animal. Indicate both parental 
strains, e.g. T, HT; and include details of the genetic characteristics. This 
field is limited to 60 characters. If all of the relevant information cannot 
be entered here, provide further details in the 'Comments' section. 
Dose level (mg/kg) Units (mg/kg) are pre-defined in SNIF, therefore enter only numerical 
value. At least two dose levels should be used, and so it may be necessary 
to describe the dose levels in more detail in the 'Comments' section. 
Doses producing Free Text. Describe any toxic effects observed during the period of the  
toxicity study. 
Route of e.g. Oral, Dermal, or Inhalation, etc. In SNIF, only two characters are  
administration available for this entry, as follows: 
OR (oral) DM (dermal) IN (inhalation) 
IV (intra-venous) IM (intra-muscular) IP (intra-peritoneal) 
SU (sub-cutaneous) 
Normally single treatment, so indicate in 'Comments' section on which 
day this was administered, e.g. 8, 9 or 10. 
Vehicle The vehicle should be described clearly and in full (not abbreviated). 
Also, state whether the test substance is in solution or suspension. SNIF 
permits up to 60 characters for this entry. 
e.g. Distilled water; 0.5% aqueous carboxymethylcellulose. 
Observations Free text. 
Result Free text. Report all three classes of spots scored, i.e. WMVS, MDS, RS 
Method e.g. 87/302/EEC, B.24 (Mouse Spot Test). 
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Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
Comments Free Text. Comment on the quality of the study; strains used; dosing 
regime; and also on the use of negative and positive control data. 
4.3.36 Mouse Heritable Translocation Test 
Species/strain Mouse (specify the strain) 
Dose level (mg/kg) Units (mg/kg) are pre-defined in SNIF, therefore enter only numerical 
value. Normally the Maximum Tolerated Dose would be used. However, 
if more dose levels are used they should be described in the 'Comments' 
section. 
Doses producing Describe observations of toxic effect. 
toxicity 
Route of e.g. Oral, Dermal, or Inhalation, etc. In SNIF, only two characters are  
administration available for this entry, as follows: 
OR (oral) DM (dermal) IN (inhalation) 
IV (intra-venous) IM (intra-muscular) IP (intra-peritoneal) 
SU (sub-cutaneous) 
Vehicle The vehicle should be described clearly and in full (not abbreviated). 
Also, state whether the test substance is in solution or suspension. SNIF 
permits up to 60 characters for this entry. e.g. Distilled water, 0.5 % 
aqueous carboxymethylcellulose. 
Observations Free text. 
Result Free text. Indicate how heterozygosity was determined e.g. 
a) fertility testing of F1 males, or 
b) cytogenetic analysis of F1 males. 
Method e.g. 87/302/EEC, B.25 (Mouse Heritable Translocation Assay). 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by 
for test entering the appropriate code. 
Comments Free Text. Comment on mean litter sizes obtained; number of F1 
offspring; whether F1 male progeny only were assessed or both males 
and females; and on the use of negative and positive control data. 
4.3.37 Sex Linked Recessive Lethal in Drosophila 
Species/strain Indicate genotype of males, e.g. wild-type, and of females, e.g. Muller-5. 
Dose level (mg/kg) Units (mg/kg) are pre-defined in SNIF, therefore enter only numerical 
value. Normally, three dose levels are used, and so it may be necessary 
to describe the dose levels in more detail in the 'Comments' section. 
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Doses producing Describe in free text. 
toxicity 
Route of e.g. exposure to gas, vapour, etc., or dosed in diet. 
administration 
Vehicle The vehicle should be described clearly and in full (not abbreviated). 
Also, state whether the test substance is in solution or suspension. SNIF 
permits up to 60 characters for this entry. e.g. Distilled water, 0.5 % 
aqueous carboxymethylcellulose. 
Observations Free text. 
Result Indicate whether +ve or  -ve mutagenic effect. 
Method e.g. 87/302/EEC, B.20 (Sex-linked Recessive Lethal Drosophila Assay) 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by 
for test entering the appropriate code. 
Comments: Free text. Comment on the quality of the study, and on the use of negative 
and positive control data. 
 
4.4.00  REPRODUCTION TOXICITY 
The test methods in Annex V (currently in 87/302/EEC) should normally be used. However, 
when there is clear scientific justification, other methods may be used. 
Nevertheless, it should be noted that the OECD reproductive toxicity screening tests (guidelines 
421 and 422), which have been developed specifically for priority setting of existing chemicals, 
are not considered acceptable for classification of notified new substances. 
For level 1 and level 2 the strategy for assessing the requirement for reproductive toxicity 
studies at higher supply levels is described in the Technical Guidance. 
As indicated in the Technical Guidance Document, most regulatory authorities no longer require 
a three-generation study. 
There is no EC or OECD test method for a developmental study on peri- and post-natal effects. 
4.4.10 Reproductivity screening study (for the record) 
4.4.20 Reproductive Studies One Generation 
Limit test (Y/N) Single character entry. Indicate Y(es) or N(o). 
Details of the dose used should be entered into the 'Comments' section. 
Species/strain Specify the species and (strain) of the test animal. 
e.g. Rat (Wistar), Mouse (CD-1). 
Route of e.g. Oral, Dermal, or Inhalation, etc. In SNIF, only two characters are  
administration available for this entry, as follows: 
 53
OR (oral) DM (dermal) IN (inhalation) 
IV (intra-venous) IM (intra-muscular) IP (intra-peritoneal) 
SU (sub-cutaneous) 
Method of  If oral, indicate whether by gavage or in diet/drinking water.  
administration  If inhalation, indicate whether whole body or nose-only. 
or of exposure 
Vehicle The vehicle should be described clearly and in full (not abbreviated). 
Also, state whether the test substance is in solution or suspension. SNIF 
permits up to 60 characters for this entry. 
e.g. Distilled water; 0.5% aqueous carboxymethylcellulose. 
Mass median  Free Text. Enter the size range, erg. 2.2µ, or 75% of particles < 5µ. 
aerodynamic  
diameter (for liquid  
and solid aerosols) 
Duration of Enter the daily exposure period as an integer. 
exposure per day  
(inhalation or  
dermal)...hours 
Dosing Regime Only a single integer ('5' or ‘7’) is permitted here.  
(5 or 7 days/week) 
Males days Give information about dosing/exposure period 
Females days e.g. for males, continual from 70 days prior to mating, for females, from 
14 days prior to mating, through gestation and up to 21 days post-
partum. 
Results Positive effects should be related to treatment and exposure level. If no 
sign of toxicity considered attributable to the test substance is seen, this 
should be stated. Important effects should be described quantitatively as 
a deviation from the values seen in control animals. 
Sex Dose/Conc. Provide this information in Table format. Unlimited number of lines is 
Number of animals permitted. Units (mg/kg) are pre-defined in SNIF, so only numerical 
Group No entries are permissible: 
M 0 20 1 
M 10 20 2 
M 100 20 3 
M 1000 20 4 
F 0 20 1 
F 10 20 2 
F 100 20 3 
F 1000 20 4 
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Number of Litters Report the number of litters produced at birth for each group. These are 
per Dose/Conc. normally not standardised, e.g. to 8, thereafter. 
Dose level (mg/kg) Units (mg/kg) are pre-defined in SNIF, therefore enter only numerical 
value. Normally at least three dose levels should be used, and so it will 
be necessary to describe the dose levels in more detail in the 'Comments' 
section. 
Effects on parental The focus of attention for this study is on adverse effects on reproduction. 
animals The focus of attention for this section is on evidence of impaired 
reproductive ability in the parental animals. 
Report any signs of toxic effect which may have contributed to 
impairment of reproductive ability; deaths, adverse effect on body 
weight, food and water consumption, etc., and signs of ill-health 
throughout. Include observations of adverse effect seen at Necropsy. 
Comment on the behaviour of the dams during pregnancy and through 
the period of lactation.  
Comment on adverse effect, or no adverse effect, on reproductive 
performance, e.g. success in mating, pregnancy, parturition. 
Effects on F1 The focus of attention for this section is on evidence of adverse effect on  
generation survival, growth and development of the offspring. 
Comment on adverse effect, or no adverse effect, on numbers at birth, 
and on survival and growth through lactation. Include comments on any 
adverse effect on body weight, or abnormal behavioural characteristics. 
Include observations of adverse effect seen at Necropsy, at weaning. 
Method e.g. 87/302/EEC, B.34 (single generation reproduction study) 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by 
for test entering the appropriate code. 
Comments Describe the mating schedule used. 
e.g. 1:1, producing F1 or 1:2, producing F1A and F1B. 
If dosed in diet/drinking water, include here conversions from ppm to 
mg/kg. 
4.4.30 Reproductive Studies Two or Three Generations 
Limit test (Y/N) Single character entry. Indicate Y(es) or N(o). 
 Details of the dose used should be entered into the 'Comments' section. 
Species/strain Specify the species and (strain) of the test animal. 
 e.g. Rat (Wistar), Mouse (CD-1). 
Route of e.g. Oral, Dermal, or Inhalation, etc. In SNIF, only two characters are  
administration available for this entry as follows: 
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OR (oral) DM (dermal) IN (inhalation) 
IV (intra-venous) IM (intra-muscular) IP (intra-peritoneal) 
SU (sub-cutaneous) 
The oral route is usually chosen, but other routes may have better 
justification. 
Method of If oral, indicate whether by gavage or in diet/drinking water. 
administration If inhalation, indicate whether whole body or nose-only. 
or of exposure 
Vehicle The vehicle should be described clearly and in full (not abbreviated). 
Also, state whether the test substance is in solution or suspension. SNIF 
permits up to 60 characters for this entry. 
 e.g. Distilled water; 0.5% aqueous carboxymethylcellulose. 
Mass median Free Text. Enter the size range, e.g. 2.2µ, or 75% of particles < 5µ. 
aerodynamic diameter 
(for liquid and 
solid aerosols) 
Duration of Enter the daily exposure period as an integer  
exposure per day  
(inhalation or  
dermal)...hours 
Dosing Regime Only a single integer ('5' or’7’) is permitted here. 
(5 or 7 days/week) Give below information about dosing/exposure period for each 
generation. 
 e.g. F0, F1 (or F1A and F1B), F2 (or F2A and F2B), as appropriate: 
Explain which generations were dosed/exposed, and for what period: 
Males days Females days 
F0 
F1 
F2 
Sex Dose/Conc. Provide this information in Table format, for each Generation of the  
Number of animals study. Unlimited number of lines is permitted. 
Group No 
F0 Generation 
F1 Generation 
F2 Generation 
M 0 20 1 
M 10 20 2 
M 100 20 3 
M 1000 20 4 
F 0 20 1 
F 10 20 2 
F 100 20 3 
F 1000 20 4 
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Number of litters  Report the numbers at birth. Indicate in 'Comments' if litters were  
per generation standardised, e.g. to 8, thereafter. 
Group 1 Group 2 Group 3 Group 4 
F1 
F2 
F3 
Results Positive effects should be related to treatment and exposure level. If no 
sign of toxicity considered attributable to the test substance is seen, this 
should be stated. Important effects should be described quantitatively as a 
deviation from the values seen in control animals. 
First Generation  
Stage 
Effects on parental The focus of attention for this study is on adverse effects on  
animals reproduction. The focus of attention for this section is on evidence of 
 impaired reproductive ability in the parental animals. 
Report any signs of toxic effect which may have contributed to 
impairment of reproductive ability; deaths, adverse effect on body 
weight, food and water consumption, etc., and signs of ill-health 
throughout. Include observations of adverse effect seen at Necropsy. 
Comment on the behaviour of the dams during pregnancy and through 
the period of lactation. 
Comment on adverse effect, or no adverse effect, on reproductive 
performance, e.g. success in mating, pregnancy, parturition. 
Effects on F1 The focus of attention for this section is on evidence of adverse effect on  
generation survival,growth and development of the offspring. Specify if F1A or F1B. 
Comment on adverse effect, or no adverse effect, on numbers at birth, 
and on survival and growth through lactation. Include comments on any 
adverse effect on body weight, or abnormal behavioural characteristics. 
Include observations of adverse effect seen at Necropsy, at weaning. 
Second generation 
stage 
Effects on parental See first generation stage (for parents). Specify if F1A or F1B. 
animals 
(F1 generation) 
Effects on F2  See first generation stage (for offspring). Specify if F2A or F2B. 
generation 
Third generation 
stage 
Effects in parental See first generation stage (for parents). Specify if F2A or F2B. 
animals 
(F2 generation) 
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Effects on F3 See first generation stage (for offspring). 
generation 
Method e.g. 87/302/EEC, B.35 (two generation reproduction study). 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
Comments Free Text. Comment on correlation of findings with preceding repeat-
dose studies and/or preliminary dose-range-finding study for 
reproductive studies. 
If dosed in diet/drinking water, include here conversions from ppm to 
mg/kg. 
4.4.40 Developmental Toxicity Teratogenecity 
Limit test (Y/N) Single character entry. Indicate Y(es) or N(o) 
 Details of the dose used should be entered into the 'Comments' section. 
Species/strain Specify the species and (strain) of the test animal. 
 e.g. Rat (Sprague-Dawley); Rabbit (New Zealand White) 
Route of e.g. Oral, Dermal, or Inhalation, etc. In SNIF, only two characters are 
administration available for this entry, as follows: 
OR (oral) DM (dermal) IN (inhalation) 
IV (intra-venous) IM (intra-muscular) IP (intra-peritoneal) 
SU (sub-cutaneous) 
The oral route is usually chosen, but other routes may have better 
justification. 
Method of  If oral, indicate whether by gavage or in diet/drinking water. If  
administration inhalation, indicate whether whole body or nose-only. 
or of exposure 
Vehicle The vehicle should be described clearly and in full (not abbreviated). 
Also, state whether the test substance is in solution or suspension. SNIF 
permits up to 60 characters for this entry. e.g. Distilled water; 0.5% 
aqueous carboxymethylcellulose. 
Mass median  Free Text. Enter the size range, e.g. 2.2µ, or 75% of particles < 5µ. 
aerodynamic  
diameter,  
(for liquid and 
solid aerosols) 
Duration of  Enter the daily exposure period as an integer. 
exposure per day  
(inhalation or  
dermal)...hours 
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Dosing Regime Only a single integer ('5' or '7') is permitted here. 
(5 or 7 days/week) Give below information about dosing/exposure period for each  
 generation,  
e.g. F0, F1, (or F1A and F1B), F2 (or F2A and F2B), as appropriate: 
Number of dams, Units (mg/kg) are pre-defined in SNIF, therefore enter only numerical  
doses and group  values for dose. 
numbers 
Dose or Conc. (mg/kg) Number of Dams Group No 
e.g.  
0 15 1 
5 15 2 
25 15 3 
125 15 4 
Results in relation Positive effects should be related to treatment and exposure level. If no  
to dose levels/conc. sign of toxicity considered attributable to the test substance is seen, this  
 should be stated. Important effects should be described quantitatively as a 
 deviation from the values seen in control animals. 
Effects on Dam Report deaths, effects on body weight, adverse effects on behaviour, and 
signs of ill-health. 
Effects on foetus Report observations at Caesarian section, signs of abnormality, adverse  
(Gross) effect on body weight, reduced size, etc. 
Effects on foetus Report observations from open dissection of foetuses (visceral  
(Soft tissue) examination) and/or from serial slices of fixed whole foetuses. 
Effects on foetus Report observations from stained foetal skeletal preparations, or x-ray  
(Skeletal) examinations. 
Dose at which no Enter numerical data to indicate No Observed Adverse Effect Level, or,  
toxic effects were if this is not established, enter '<' lowest dose in study. 
observed: 
a) on dam mg/kg/day, or mg/l/h/day 
b) on embryo/foetus mg/kg/day, or mg/l/h/day 
Method e.g. 87/302/ EC, B.31 (Developmental Toxicity Study) 
Body responsible Select the Testing Facility from the look-p list provided in SNIF, by  
for test entering the appropriate code. 
Comments Comment on method of insemination and pregnancy rate achievement in 
all groups. Consider signs of toxic effect in the dams when interpreting 
adverse effects in the foetus. 
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4.5.00  TOXICOKINETICS 
4.5.10  Assessment of Toxicokinetic Behaviour 
General 
The assessment of the toxicokinetic behaviour of the substance is required to the extent that it 
can be made from evidence of all toxicological studies conducted and other relevant information 
to date on the test substance or its analogues. The aim is to consider all available information so 
that the most informed assessment about risk, and the need for further testing, can be made. It is 
a written assessment based on the base set data. 
Include consideration of chemical structure, molecular weight, physical form, particle size, 
vapour pressure, water solubility, Log PoW, and information on hydrolysis. Evidence from 
structure activity relationships (SAR) and information about analogous structures may also 
provide useful information, i.e. what is known about absorption, distribution, metabolism and 
excretion of similar substances. 
Observations of local and systemic effects in toxicity studies should be considered and 
differences in toxicity for routes other than those addressed in the base set studies. Consider also 
the potential for bioaccumulation and the influence of metabolic activation on the activity of the 
substances as observed in in-vitro mutagenicity assays. 
4.5.20  Toxicokinetic Study 
This index is used to summarise an experimental study of toxicokinetics. 
Objective of the Free Text Describe the purpose of the study. 
study e.g. Absorption and distribution analysis, Identification of excreted 
metabolites. 
Test substance Enter Y(es) or N(o). 
labelled (Y/N) 
Details of label Free Text. Indicate the isotope used, the molecule that was labelled, e.g. 
test substance or a metabolite, and the position of the label. 
Species/strain Specify the species and (strain) of the test animal. 
 e.g. Rat (Sprague-Dawley). Indicate if the animals were metabolically 
induced, e.g. with Aroctor. 
Route of e.g. Oral, Dermal, or Inhalation, etc. In SNIF, only two characters are 
administration available for this entry, as follows: 
OR (oral) DM (dermal) IN (inhalation) 
IV (intra-venous) IM (intra-muscular) IP (intra-peritoneal) 
SU (sub-cutaneous) 
The oral route is usually chosen, but other routes may have better 
justification. 
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Method of  e.g. by gavage (oral), and indicate if single or repeated administration. 
administration  
and exposure 
Vehicle The vehicle should be described clearly and in full (not abbreviated). 
Also, state whether the test substance is in solution or suspension. SNIF 
permits up to 60 characters for this entry. e.g. Distilled water; 0.5 % 
aqueous carboxymethylcellulose. 
Mass median  Free Text. Enter the size range, e.g. 2.2µ, or 75% of particles < 5µ. 
aerodynamic  
diameter (for  
liquid and 
solid aerosols) 
Duration of Enter the daily exposure period as an integer. 
exposure per day 
(inhalation or  
dermal)....hours 
Dosing Regime Only a single integer ('5' or '7') is permitted here. 
(5 or 7 days/week) If the study involves only a single administration, leave this area blank. 
Results Enter the dose-group information in the Table below. Units (mg/kg) are 
pre-defined in SNIF, therefore enter only numerical values. If the dosing 
units are not mg/kg, describe the conversion in the 'Comments' section. 
Sex  Dose/conc. (mg/kg) Number of animals Group No 
M 100 5 1 
M 1000 5 2 
F 100 5 3 
F 1000 5 4 
Results Free Text. Summarise the study clearly and concisely. Important aspects 
to consider are Site, timing, and frequency of sampling Tissues examined 
Half-lives for absorption and elimination Bio-availability Metabolites 
identified 
However, do not interpret or discuss the results in this section. The dis-
cussion and conclusions should be in the 'Comments' section. 
Method If a published protocol is used, provide the reference here. 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by 
for test entering the appropriate code. 
Comments Free Text. Keep comments clear and concise. Enter details of the 
analytical methods used, e.g. LSC, GC, TLC, HPLC, etc. Include here 
discussion of the results and conclusion(s) of the study. 
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4.6.00  CHRONIC TOXICITY AND CARCINOGENICITY 
The strategy for assessing the requirement for a Chronic Toxicity Study at higher supply levels is 
described in the Technical Guidance, as is the need to conduct a Carcinogenicity Study. 
4.6.10 Chronic Toxicity Test 
Species/strain Specify the species and (strain) of the test animal. 
 e.g. Rat (Sprague-Dawley). The Rat is the preferred species. However 
data from studies using other species can be useful and should not be 
rejected. 
Dose or conc. This is the dose or concentration at which no substance-related 
at which no toxic adverse effect of toxicological significance was observed. It should 
effects were be noted that this dose level will usually be higher than that at which 
observed “No effect" is observed. 
mg/kg/day or, Enter value. 
mg/1/…/h/day If not established, give '<' lowest dose used in the study. 
Route of e.g. Oral, Dermal, or Inhalation, etc. In SNIF, only two characters are 
administration available for this entry as follows: 
OR (oral) DM (dermal) IN (inhalation) 
IV (intra-venous) IM (intra-muscular) IP (intra-peritoneal) 
SU (sub-cutaneous) 
Method of If oral, indicate whether by gavage or in diet/drinking water.  
administration If inhalation, indicate whether whole body or nose-only. 
or of exposure 
Vehicle The vehicle should be described clearly and in full (not abbreviated). 
Also, state whether the test substance is in solution or suspension. SNIF 
permits up to 60 characters for this entry. e.g. Distilled water; 0.5 % 
aqueous carboxymethylcellulose. 
Mass median  Free Text. Enter the size range, e.g. 2.2µ, or 75 % of particles < 5µ. 
aerodynamic  
diameter(for liquid 
and solid aerosols) 
Duration of Enter the daily exposure period as an integer. 
exposure per day  
(inhalation or 
dermal)...hours 
Dosing Regime Only a single integer ('5' or '7') is permitted here.  
(5 or 7 days/week) 
Results Positive effects should be related to treatment and exposure level. If no 
sign of toxicity considered attributable to the test substance is seen, this 
should be stated. Important effects should be described quantitatively as a 
deviation from the values seen in control animals. 
    62
Sex Dose/conc. (mg/kg) Number of animals Group No 
M Enter the required numerical data in the Table  
F 
Results (in relation Where appropriate, signs listed should be related to exposure level, time  
to dose levels/ conc.) of onset, and duration. If no sign of toxicity considered attributable to the 
 test substance is seen, this should be stated. Important effects should be 
 described quantitatively as a deviation from the values seen in control
 animals. 
1) Clinical Free Text. Clear, concise and organised. Signs listed should be only those  
observations considered attributable to the test substance. Clinical observations 
 include deaths, effects on body weight, food and water consumption, and
 any signs of ill-health. 
2) Laboratory As 1) above, covering haematology, blood chemistry and urinalysis 
findings values. 
3) Effect in organs Summarise observations at necropsy (macroscopic) and at microscopic 
(general) examination. It may be appropriate to distinguish effects seen in animals
 that died during the study (unscheduled) from those in animals killed as
 scheduled. 
Effect in organs Provide a summary of masses observed at necropsy (macroscopic) and 
(tumours) neoplasms identified after microscopic examination. 
Dose or conc. This is the dose or concentration at which no substance-related 
at which no effect adverse effect was observed. It should be noted that this dose level 
was observed  will usually be lower than that at which "No toxic effect" is observed. 
Mg/kg/day or, If not established, give '<' lowest dose in this study. 
mg/l for...hours/day 
Method e.g. 87/302/EEC, B.30 (12 months Chronic Toxicity Study) 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by 
for test entering the appropriate code. 
Comments Free Text. Comment on the quality of the study, especially if conducted 
by he inhalation route. 
Report unusual circumstances which may have influenced the outcome of 
he study or the reliability of the results, e.g. intercurrent disease. 
If dosing was conducted in diet, or in drinking water, include here the 
calculated values for mean daily dosing, in mg/kg. 
Present the interpretation of results in order to justify the establishment of 
the No Observed Adverse Effect Level: 
e.g. It is not possible to establish a reliable and unequivocal no toxic 
effect level for this substance. 
e.g. As the effects observed at 100 and 1000 mg/kg were only minor, 
the dose at which no toxic effect occurred is considered to be 1000 
mg/kg. 
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4.6.20 Carcinogenicity Tes  t
The strategy for assessing the need to conduct a Carcinogenicity Study at higher supply levels is 
described in the Technical Guidance. 
Species/strain Specify the species and (strain) of the test animal. 
e.g. Rat (Sprague-Dawley). The Rat is the preferred species. However 
data from studies using other species can be useful and should not be 
rejected. 
Dose or conc. This is the dose or concentration at which no substance-related adverse  
at which no toxic effect of toxicological significance was observed. It should be noted that 
effects were this dose level, which can indicate the need for R48, "Serious damage to, 
observed health" to be applied will usually be higher than that at which No, effect"
 is observed. 
Mg/kg/day or, Enter value. 
Mg/l/…/h/day If not established, give '<' lowest dose used in the study. 
Route of e.g. Oral, Dermal, or Inhalation, etc. In SNIF, only two characters are 
administration available for this entry, as follows: 
OR (oral) DM (dermal) IN (inhalation) 
IV (intra-venous) IM (intra-muscular) IP (intra-peritoneal) 
SU (sub-cutaneous) 
Method of  If oral, indicate whether by gavage or in diet/drinking water. If  
administration inhalation, indicate whether whole body or nose-only. 
or of exposure 
Vehicle The vehicle should be described clearly and in full (not abbreviated). 
Also, state whether the test substance is in solution or suspension. SNIF 
permits up to 60 characters for this entry. e.g. Distilled water; 0.5 % 
aqueous carboxymethylcellulose. 
Mass median Free Text. Enter the size range, e.g. 2.2µ, or 7 5% of particles < 5µ. 
aerodynamic 
diameter (for liquid 
and solid aerosols) 
Duration of Enter the daily exposure period as an integer  
exposure per day  
(inhalation or  
dermal)...hours 
Dosing Regime (5 or  Only a single integer ('5' or ‘7’) is permitted here. 
7 days/week) 
Results Positive effects should be related to treatment and exposure level. If no 
sign of toxicity considered attributable to the test substance is seen, this 
should be stated. Important effects should be described quantitatively as a 
deviation from the values seen in control animals. 
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Sex Dose/conc. (mg/kg) Number of animals Group No 
M Enter the required numerical data in the Table 
F 
1) Clinical Free Text. Clear, concise and organised. Signs listed should be only those  
observations considered attributable to the test substance. Clinical observations 
 include deaths, effects on body weight, food and water consumption, and
 any signs of ill-health. 
2) Laboratory As 1) above, covering haematology, blood chemistry and urinalysis  
findings values. 
3) Effect in organs Summarise observations at necropsy (macroscopic) and at microscopic  
(general) examination. It may be appropriate to distinguish effects seen in animals 
 that died during the study (unscheduled) from those in animals killed as
 scheduled. 
Effect in organs Provide a summary of masses observed at necropsy (macroscopic) and  
(tumours) neoplasms identified after microscopic examination. 
Dose or conc. This is the dose or concentration at which no substance-related adverse  
at which no effect effect was observed. It should be noted that this dose level will usually be  
was observed  lower than that at which "No toxic effect" is observed. 
Mg/kg/day or, If not established, give '<' lowest dose in this study. 
mg/l for...hours/day 
Method e.g. 87/302/EEC, 13.32 (Rat Carcinogenicity Study). 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
Comments Free Text. Comment on the quality of the study, especially if conducted 
by the inhalation route. 
Report unusual circumstances which may have influenced the outcome of 
the study or the reliability of the results, e.g. intercurrent disease. 
If dosing was conducted in diet, or in drinking water, include here the 
calculated values for mean daily dosing, in mg/kg. 
Present the interpretation of results in order to justify the establishment of 
the No Observed Adverse Effect Level : 
e.g. It is not possible to establish a reliable and unequivocal no toxic 
effect level for this substance. 
e.g. As the effects observed at 100 and 1000 mg/kg were only minor, 
the dose at which no toxic effect occurred is considered to be 1000 
mg/kg. 
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4.6.30 Combined Chronic Toxicity/Carcinogenicity Test 
The strategy for assessing the need to conduct a Chronic/Carcinogenicity Study at higher supply 
levels is described in the Technical Guidance. 
Species/strain Specify the species and (strain) of the test animal, e.g. Rat (F344). The 
Rat is the preferred species. However data from studies using other 
species can be useful and should not be rejected. 
Dose or conc. This is the dose or concentration at which no substance-related adverse  
at which no toxic effect of toxicological significance was observed. It should be noted that  
effects were this dose level, which can indicate the need for R48, "Serious damage to  
observed health" to be applied, will usually be higher than that at which “No
 effect" is observed. 
mg/kg/day or, Enter value. 
mg/l/…/h/day If not established, give '<' lowest dose used in the study. 
Route of e.g. Oral, Dermal, or Inhalation, etc. In SNIF, only two characters are 
administration available for this entry, as follows: 
OR (oral) DM (dermal) IN (inhalation) 
IV (intra-venous) IM (intra-muscular) IP (intra-peritoneal) 
SU (sub-cutaneous) 
Method of If oral, indicate whether by gavage or in diet/drinking water. If  
administration  inhalation, indicate whether whole body or nose-only. 
or of exposure 
Vehicle The vehicle should be described clearly and in full (not abbreviated). 
Also, state whether the test substance is in solution or suspension. SNIF 
permits up to 60 characters for this entry. e.g. Distilled water; 0.5% 
aqueous carboxymethylcellulose. 
Mass median Free Text. Enter the size range, e.g. 2.2µ, or 75% of particles < 5µ. 
aerodynamic 
diameter(for liquid 
and solid aerosols) 
Duration of Enter the daily exposure period as an integer. 
exposure per day  
(inhalation or  
dermal)...hours 
Dosing Regime Only a single integer ('5' or ‘7‘ is permitted here.  
(5 or 7 days/week) 
Results Positive effects should be related to treatment and exposure level. If no 
sign of toxicity considered attributable to the test substance is seen, this 
should be stated. Important effects should be described quantitatively as a 
deviation from the values seen in control animals. 
    66
Sex Dose/conc. (mg/kg) Number of animals Group No  
M Enter the required numerical data in the Table  
F 
Results (in relation Where appropriate, signs listed should be related to exposure level, time  
to dose levels/ of onset, and duration. If no sign of toxicity considered attributable to the  
concentration) test substance is seen, this should be stated. Important effects should be
 described quantitatively as a deviation from the values seen in control
 animals. 
1) Clinical Free Text. Clear, concise and organised. Signs listed should be only those  
observations considered attributable to the test substance. Clinical observations include
 deaths, effects on body weight, food and water consumption, and any
 signs of ill-health. 
2) Laboratory As 1) above, covering haematology, blood chemistry and urinalysis  
findings values. 
3) Effect in organs Summarise observations at necropsy (macroscopic) and at microscopic  
(general) examination. It may be appropriate to distinguish effects seen in animals
 that died during the study (unscheduled) from those in animals killed as
 scheduled. 
Effect in organs: Provide a summary of masses observed at necropsy (macroscopic) 
(tumours) and neoplasms identified after microscopic examination. 
Dose or conc. This is the dose or concentration at which no substance-related adverse  
at which no effect effect was observed. It should be noted that this dose level will usually be  
was observed lower than that at which "No toxic effect" is observed. 
mg/kg/day or, mg/l If not established, give '<' lowest dose in this study.  
for...hours/day 
Method e.g. 87/302/EEC (Combined Chronic/Carcinogenicity Study). 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by 
for test entering the appropriate code. 
Comments Free Text. Comment on the quality of the study, especially if conducted 
by the inhalation route. 
Report unusual circumstances which may have influenced the outcome of 
the study or the reliability of the results, e.g. intercurrent disease. 
If dosing was conducted in diet, or in drinking water, include here the 
calculated values for mean daily dosing, in mg/kg. 
Present the interpretation of results in order to justify the establishment 
ofthe No Observed Adverse Effect Level: 
e.g. It is not possible to establish a reliable and unequivocal no toxic 
effect level for this substance. 
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e.g. As the effects observed at 100 and 1000 mg/kg were only minor, 
the dose at which no toxic effect occurred is considered to be 1000 
mg/kg. 
 
4.7.00  ADDITIONAL TOXICOLOGICAL STUDIES 
General 
These tests are not required for the reduced and base-set notifications (Annex VII A/B/C) but 
may be included voluntarily or they may, in certain circumstances, be requested by the 
Competent Authority immediately post base-set to clarify the results of the (reduced) base-set 
tests. 
When the quantity of the substance supplied reaches the trigger points for supplementary 
notification (level 1 and level 2) the need for further toxicity tests should be considered. 
If data on additional acute tests are to be included, then the results should be presented in the 
same format as for other acute tests (see sections 4.1.10, 4.1.20 and 4.1.30) 
Tests for which no existing format should be given in this section. 
End point e.g. Lymph node cell proliferation as an indication of skin sensitisation  
investigated potential. 
Description of the Include number, sex, and strain of mouse used, and details of the dosing  
essential features regime. 
of the test method 
Results Indicate whether +ve or -ve response shown. 
Test procedure e.g. Mouse Local Lymph Node Assay (Toxicology Methods, 1, 30-43 
used (1991). 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
Comments Give summarised details of criteria for interpreting +ve response, e.g. 
est/control ratio for lymph node cell proliferative response > 3. 
If +ve result, indicate if labelling recommended, e.g. R43 
If -ve result, comment if approved study, e.g. GPIVIT, will be requested. 
Comment on the use of negative and positive control data. 
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SECTION A5 ECOTOXICOLOGICAL STUDIES 
 
5.1.00 EFFECTS ON ORGANISMS 
General 
Prior to conducting toxicity tests on aquatic organisms, it is important to obtain information on 
the solubility and the stability of the substance in the test medium, since these may differ from 
the result obtained under the water solubility test (see section 3.0.60). 
A preliminary stability study will often be useful. If the loss of concentration over the test period 
is < 20%, either a static, semi-static, or flow-through exposure regime can be used. If the 
measured concentration drops by > 20%, a static system should not be used if suitable 
alternatives are available. If the loss of concentration over 24 hours is < 20% then, for the fish 
test, either a semi-static or a flow-through procedure can be used. If the loss of concentration is > 
20% over 24 hours, a flow-through regime is recommended. 
As required by Annex V, concentrations of test substance should be measured at least at the 
beginning and at the end of the test. In practice, it will normally be necessary to monitor this 
concentration more frequently. The LC50's, EC50's and NOEC’s should be calculated based on 
the measured concentrations. 
Where the measured concentrations are close to the nominal concentration, it is acceptable to 
calculate the LC50's, EC50's and NOEC's based on the nominal concentrations of the tested 
substance. In other cases, the geometric average measured concentration should be used. 
A special case arises where substances decompose (hydrolyse, polymerize etc.) rapidly in the test 
media. When the DT50 < 4 hours a static test should be conducted to include the degradation 
products. When the DT50 > 12 hours, the parent substance should be studied using the 
appropriate exposure regime. When the DT50 falls between 4 and 12 hours, contact the 
Competent Authority to discuss the testing procedure. 
For poorly soluble substances, it will not normally be necessary to conduct tests above the 
solubility limit in the test media. It may be useful, however, to conduct such tests in the presence 
of undissolved substance to ensure the maintenance of the exposure concentration during the 
test. Where possible, the test organisms should be physically separated from the undissolved 
fraction to avoid physical effects. Verification of the concentration of the dissolved substance 
should be made following centrification or filtration of the exposure media. The LC50's, EC50's 
and NOEC's should be calculated based on this dissolved concentration. Where no mortalities or 
effects are observed, the LC50, EC50, and NOEC should be recorded as being above the stated 
solubility limit. 
Test methods for certain ecotoxicological properties are not yet included in Annex V. If national 
standard methods exist, then the additional information these tests provide for the purpose of 
assessment should be included in the notification. 
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5.1.01 Acute Toxicity for Fish 
LC50 The LC50 values should be given at 24, 48, 72 and 96h to evaluate the 
dose duration-effect relationship. All values quoted should be based upon 
actual and not nominal concentrations. 
No-observed effect State the concentration without effect (physiological, behavioral etc.) at 
conc. (NOEC) 96h. A NOEC might give an indication for delayed effects. 
at 96h An LC0 is not the same as a NOEC and is not an acceptable substitute. 
Species Specify the species and (strain) of the test animal, e.g. Rainbow trout or 
Zebra-fish 
Test The type of test should be stated; single entry only 'ST' (static), 'SS' (semi 
static), or 'FT' (flow-through). 
Loss in conc. of the Knowledge of any % loss in concentration during the test period is  
test substance essential, especially for poorly water soluble substances since this will 
 influence the calculation of the LC50 values. 
Identity and It is essential to have information on the auxiliary solvents and/or  
conc. of auxiliary dispersion techniques used in the tests. If such devices are used it is  
solvents necessary that appropriate "solvent" controls are also employed.  
Water hardness This information is necessary as for some substances the water hardness 
has a significant impact upon solubility and hence toxicity. 
Dissolved oxygen The minimum concentration of oxygen in water should be at least 80 %  
conc. in water of the air-saturation value. The oxygen concentration should be measured  
 daily. 
Method e.g. Annex V, C. 1. 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
Comments Comments should be made on any aspects of the test which may 
influence the results. Comments should be full but concise 
5.1.02 Acute Toxicity for Daphnia 
EC50 The EC50 values should be given at 24 and 48h to evaluate the dose 
duration-effect relationship. All values quoted should be based upon 
actual and not nominal concentrations. 
No-observed State the concentration without effect (physiological, behavioral etc.)  
effect conc. at 48h. A NOEC might give an indication for delayed effects. An EC0 is  
(NOEC)at 48h not the same as a NOEC and is not an acceptable substitute. 
Species Specify the species of the test animal; single entry only DM' (Daphnia 
magna) or 'DP' (Daphnia pulex). 
Test The type of test should be stated; single entry only 'ST' (static), 'SS' (semi 
static), or 'FT' (flow-through). 
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Loss in conc. of Knowledge of any % loss in concentration during the test period is  
the test substance essential, especially for poorly water soluble substances since this will 
 influence the calculation of the EC50 values. 
Identity and It is essential to have information on the auxiliary solvents and/or 
conc. of auxiliary dispersion techniques used in the tests. If such devices are used it is 
solvents necessary that appropriate "solvent" controls are also employed. 
Water hardness This information is necessary as for some substances the water hardness 
has a significant impact upon solubility and hence toxicity, 
Dissolved oxygen The minimum concentration of oxygen in water should be at least 80 %  
conc. in water of the air-saturation value. The oxygen concentration should be measured 
 daily. 
Method e.g. Annex V, B.2. 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by 
for test entering the appropriate code. 
Comments Comments should be made on any aspects of the test which may 
influence the results. Comments should be full but concise. 
5.1.03  Growth Inhibition Test on Algae 
As for 5.1.01 above, except the as well as the NOEC for both endpoints should be submitted. 
Limit test Indicate with 'Y' (Yes) or 'N' (No) whether or not a limit test was 
performed. 
EbC50 (Biomass) The EC50 values of biomass (EbC50) and relative growth (ErC50) at 72  
ErC50 (Growth) hour values should be given to evaluate the dose duration-effect
 relationship. All values quoted should be based upon actual and not
 nominal concentrations. 
Duration of the test Specify the duration of the test in hours; e.g.72. 
Species Specify the species of the test organism, e.g. Selenastrum capricomuturn, 
ATCC or Scenedesmus subspicatus SAG. 
No-observed effect State the concentration without effect (physiological, behavioural etc.) at 
conc. for Growth 72h for growth and biomass. A NOEC(s) might give an indication for  
and Biomass (NOEC) delayed effects. An EbC0 and an ErC0 are not the same as a  
at 72h NOEC and are not an acceptable substitute. 
Type of test The type of test should be stated; 'ST' (static), 'SS' (semi-static), or 'FT' 
(flow-through). 
Loss in conc. of the Knowledge of any % loss in concentration during the test period is  
test substance essential, especially for poorly water soluble substances since this will
 influence the calculation of the EC50 values. 
Identity and It is essential to have information on the auxiliary solvents and/or  
conc. of auxiliary dispersion techniques used in the tests. If such devices are used it is  
solvents necessary that appropriate "solvent" controls are also employed. 
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Water hardness This information is necessary as for some substances the water hardness 
has a significant impact upon solubility and hence toxicity. 
Dissolved oxygen The minimum concentration of oxygen in water should be at least 80 %  
conc. in water of the air-saturation value. The oxygen concentration should be measured  
 daily. 
Method e.g. 92/69/EEC, C.3 (Algal inhibition test) 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by 
for test entering the appropriate code. 
Comments Comments should be made on any aspects of the test which may 
influence the results. Comments should be full but concise 
5.1.06 Inhibition of Microbial Activity 
General 
While this determination is not required for a reduced or base-set notification, it is nevertheless 
desirable to determine whether or not the test substance is toxic to bacteria. In those cases where 
biodegradation may be affected by the inhibitory effect of a substance on the bacteria, a test for 
bacterial inhibition should be carried out prior to undertaking the biodegradation. [if a high 
degree of toxicity is observed this will help in determining whether lack of degradation observed 
in the ready biodegradation is due to the recalcitrant properties of the test substance or to its 
toxicity.] Results obtained in this test for poorly water soluble substances should be interpreted 
with caution. 
The IC50 and/or the NOEC should be reported, as well as the duration of the test. 
5.1.07  Long Term Toxicity to Daphnia Magna 
For the time being this test will have to be carried out to the OECD guideline 202 Part B. The 
whole procedure is currently being revised and awaits completion of an inter-laboratory 
calibration study, ring test, before it can be adopted. 
EC50 (reproduction) This is to be based on actual concentrations wherever possible at 21 
days. 
No-observed effect State the concentration without effect (physiological, behavioural, etc) at  
conc. NOEC 21 days. 
Type of Test Enter 'ST' (Static), 'SS' (Semi-Static) or 'FT' (Flow-Through). The present 
SNIF proforma does not allow to enter 'ST' for Static type, so use the 
'Comment' section to provide the information. 
% Loss of test sub- It is essential to have information on loss since this must be taken into  
stance conc. account in calculating the EC50 and NOEC values. 
Identity and These must be recorded together with any dispersion techniques used. If  
conc. of auxiliary such devices are used then proper solvent controls must run in parallel  
solvents with the test series. 
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Water Hardness This must be determined and reported since it can have a significant 
effect on solubility and toxicity. 
Method e.g. OECD 202, Part B. 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
Comments Comments should be made on any aspects of the test which have an 
influence on the results. Comments should be full but concise 
5.1.08  Higher Plant Test 
Until such time as a revised protocol is available, the OECD Guideline 208 should be used. The 
test procedure is designed to study the effect of a substance on a higher plant if and when it can 
taken up through the root system. It does not apply to the study of effects of a substance taken up 
through the leaf system. It may be decided to test more than one species or strain of plant: a full 
summary is needed for each one tested. 
Species/Strain Report the name of each species or strain tested. 
Duration of test Report the duration in days. 
Soil characteristics Report the types of each soil used. Report the pH, % organic matter, etc. 
EC50 Report the value for GROWTH in mg/kg at x days. 
LC50 Report the value for EMERGENCE in mg/kg at x days. 
No observed effect Report the values of the NOEC at x days for GROWTH and  
conc. (NOEC) EMERGENCE (mg/kg). 
Units used for Report whether weights are on a dry or wet basis and length in mm. 
recording values 
Phytotoxicity Record any signs noted and the nature, e.g. lack of colour. 
Method Report the method used; e.g. OECD 208. 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by 
for test entering the appropriate code. 
Comments Comments should be made on any aspects of the test which may influence 
the results. Comments should be full but concise. 
5.1.09 Toxicity for Earthworms: Artificial Soil Test 
Species Report the species tested. 
Limit Test Enter ‘Y’ (Yes) or ‘N’ (No) only. 
Duration of Report the duration in days, normally 14. 
the test 
LC50 Report the value in mg/kg at x days, normally 14. 
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Highest conc. Calculate the LC0 value, mg/kg.  
without mortality 
Lowest conc. Calculate the LC100 value, mg/kg. 
with 100% mortality 
No observed effect Report the NOEC value, mg/kg. 
conc. (NOEC) Effects other than mortality, e.g. weight changes should be considered  
and reported in the "Comments" section. 
Soil characteristics Report the types of each soil used. Report the pH, % organic matter, etc. 
Method Report the method used. 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by 
for test entering the appropriate code. 
Comments Comments should be made on any aspects of the test which may influence 
the results. Comments should be full but concise. 
5.1.10  Fish, Longer Term Toxicity Test (normally 14 days) 
This entry may include the results of not only the 14 day prolonged toxicity study but also those 
of studies on fish reproduction and early life stages. 
Prolonged Toxicity Study: 14 days or longer 
LC50...days Report the value in mg/l. 
No observed Report the value in mg/l. 
effect conc. 
(NOEC)...days 
Lowest observed Report the value in mg/l. 
effect conc. 
(LOEC)...days 
Species Report the species tested. 
Type of test Enter 'ST' (Static), 'SS' (Semi-Static) or 'FT’ (Flow-Through). 
Duration of Test Report the actual duration of the test and the unit of duration, e.g. 14 
DYS (days). 
% loss in conc. It is essential to have information on loss since this must be taken into  
of the test account in the calculation of the LC50, and NOEC values. 
substance 
Identity and These must be recorded together with any dispersion techniques used. 
conc. of auxiliary If such devices are used then solvent controls must run in parallel with  
solvents the test series. 
Water Hardness This must be determined and reported since it can have a significant 
effect on solubility and toxicity. 
Method Report the method used. 
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Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
Comments Comments should be made on any aspects of the test which may influence 
the results. Comments should be full but concise. 
Note 
When a test has been carried out on the effect of a substance on Fish Early Life Stages, the 
parameter assessed e.g. embryo survival, time to hatch must be indicated. The NOEC and LOEC 
(Lowest Observed Effect Concentration) at x hrs in mg/l must be reported. The LOEC is not the 
same as LC0 which is a calculated value for the highest concentration causing no mortality. 
5.1.13 Avian Oral Toxicity Test 
LC50 Report the value in mg/kg. 
Species Report the species used. 
Duration of the test Report the duration of the test x days. 
Dose at which no Report the value in mg/kg. 
toxic effects were 
observed 
Number of birds, This is a Table, structured for entry of integers (number of birds), one 
doses and  text character (Sex), and numeric values (dose in mg/kg). 
group numbers 
Number of birds Male Dose mg/kg Group Number 
1 
2 
3 
4 
5 
Number of birds Female Dose mg/kg Group Number 
1 
2 
3 
4 
5 
Results 
(in relation to dose) 
1) Death Time of onset. 
2) Signs of toxicity Time of onset, duration, severity, incidence. 
Dose at which no Report the value in mg/kg. 
effect observed 
Method Report the method used. 
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Body responsible Select the Testing Facility from the look-up list provided in SNIF, by 
for test entering the appropriate code. 
Comments Comments should be made on any aspects of the test which have an 
influence on the results. Comments should be full but concise. 
5.1.14 Avian Reproduction Test 
Species Report the species used. 
Duration of feeding Report the period as x days. 
period of the test 
substance 
Dose levels of test Report the dose used in mg/kg. 
substance used 
Number of females Report the number used per dose. 
Dose at which no Report the dose in mg/kg at x days. 
effects were observed Report the parameters assessed e.g. egg production, egg viability, 
eggshell thickness. 
Results in relation Report  (1) Deaths, time of onset 
to dose (2) Signs of toxicity, time of onset, duration, severity and 
incidence 
  (3) Effects in organs. 
Method Report the method used. 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code 
Comments Comments should be made on any aspects of the test which have a  
influence on the results. Comments should be full but concise. 
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5.2.00  DEGRADATION 
General 
An agreed strategy document XI/841/86-Final is available from the Competent Authority. In the 
case of slightly soluble substances, the method of dispersion, or the use of any carrier solvent, 
must be stated - including the name of the solvent and percentage used. In these cases the 
appropriate controls must be used. Where appropriate, further tests for inhibition of the activity 
of treatment organisms (see section 5.1.06), an "inherent" or "simulation" test may be carried out 
in addition to, or substituted for, the "ready test". For certain substances an anaerobic 
degradation test may be appropriate as an alternative, or in addition to, aerobic tests. In most 
cases the COD test alone, and its relationship with the COD value, is not sufficient to give an 
indication of the potential biodegrade. 
5.2.11  Ready Biodegradability 
General 
The biodegradation curve should be drawn and in addition the experimentally determined values 
for the biodegradation experiment showing percentage degradation against time should be 
entered in the table. The biodegradation curve and experimental results should also be given for 
the reference substance. When poorly water soluble substances are tested, a description must be 
given of the nature and concentration, if appropriate, of any process and/or solvents used to 
enhance the contact between the substance and the microorganisms. 
% degradation Percentage degraded within 10-days of the start of degradation which 
point is taken as the time when 10% of the substance has been degraded 
(10-days time window). 
Classification For classification as readily biodegradable the following pass levels are 
Readily biodegr. recognized: tests based upon dissolved organic carbon >70% of 
 theoretical maxima within a 10-days time window; tests based upon 
 oxygen depletion or carbon dioxide generation >60% of theoretical 
 maxima within the 10-days time window. 
Reference substance Give the name of the reference substance 
Experimental values Measured data for both the test substance and the reference substance 
should be given in the form of a table showing day of measurement/% 
degraded. 
Degradation curve Biodegradability in percentages against time in days 
Method Indicate specific test type. 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
Comments Comments should be made on any aspects of the test which may 
influence the results. Comments should be full but concise. Record here 
the method of determination used, i.e. BOD/COD/DOC/specific. 
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5.2.12  Biochemical/Chemical Oxygen Demand (BOD/COD) 
For guidance see section 5.2.11. 
5.2.13  Inherent Biodegradability 
Degradation Report as a % 
Inherent When the results indicate or not that the substance is inherently or 
partially biodegradable or eliminated, enter 'Y' (Yes) or 'N' (No). 
Duration of the test Report the duration of the test as x days. 
Reference substance Report the name of the substance if used. 
Initial test Report the concentration stating clearly if mg/l of substances or mg/l  
substance conc. DOC. 
Source of inoculum The origin of the inoculum must be reported. 
Experimental values The measured data should be reported in a table as follows: 
Test substance Reference substance 
Day % removed Day % removed 
Degradation curve This must be supplied as a graph of time versus % degradability. 
Method This must be reported. 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
Comments Comments should be made on any aspects of the test which may influence 
the results. Comments should be full but concise. Record here the method 
of determination used, i.e. BOD/COD/DOC/specific. 
5.2.14 Biodegradation in Wastewater Simulation Test 
Removal Report as % with tolerance limit of 95% probability level and the 
respective standard deviation. 
Initial test  State this for the chosen analytical method(s) in mg17. 
substance conc. 
Duration of test Report duration as x days. 
Mode of operation Indicate which mode used, i.e. single unit, coupled unit or non-coupled 
unit. 
Source of inoculum The origin of the inoculum must be stated. 
Sludge age This must be calculated and reported. 
Retention time This must be calculated and reported. 
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Results The measured data should be reported in a table as follows: 
Test substance Reference substance 
Day %removed Day % removed 
Method Report the method used, e.g. Annex V, C. 10. 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
Comments Comments should be made on any aspects of the test which have an 
influence on the results. Include which method of determination was 
used, i.e. BOD/COD/DOC/ specific. 
5.2.15 Other Tests for Biodegradability/Elimination 
This section should be used for reporting the results of anaerobic biodegradability/ elimination 
studies and also biodegradability/ elimination in soils and sediments. The end point investigated, 
a full description of the test procedure together with the results obtained should be given. The 
method used, the name and location of the test facility and concise relevant comments should be 
reported. It is recommended that the summary be based on one of the formats for biodegradation/ 
elimination if this is possible. 
5.2.21  Hydrolysis as a Function of pH 
General 
This test need not be carried out if the substance is readily biodegradable or if the notifier can 
demonstrate, for example on the basis of chemical structure, that hydrolysis cannot be expected 
to play a significant role in the degradation of the substance in the environment. For poorly 
soluble substances (<1 mg/l), consideration may be given to omission of the test if it is not 
practical, i.e. the limit of detection of the analytical method does not allow quantification. 
pH, T °C, K value/sec, 
t½  (hrs) 
Method Report the method used, e.g. 87/302/EEC C.7. 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
Comments Comments should be made on any aspects of the test which have an 
influence on the results. Comments should be full but concise. 
 
5.3.00  ADSORPTIONIDESORPTION 
5.3.10 Adsorption/Desorption Screening Test 
For base set notification (Annex VII A) determination of Koc by HPLC analysis (Annex V test 
method C19) would normally be applicable. At upper tier notification (Annex VIII, levels 1 and 
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2) or in case of hazard concern, determination of adsorption/desorption on soils, including Koc, 
using the batch equilibrium method (Annex V test method C18) would be applicable. 
Where determination of Koc at base set (method C19) is either technically not feasible or 
scientifically invalid, estimation of Koc using QSAR prediction would be acceptable. QSAR 
calculations derive log Koc from linear extrapolation of log Kow. Either HPLC or batch 
equilibrium methods are valid for determination of Kow. For many chemicals, HPLC analysis and 
QSAR estimation of Koc would yield similar results.  
Koc values obtained from QSAR prediction are influenced according to alternative model 
equations, which should be applied as appropriate. Acceptable QSAR estimations also require 
conformity to validity criteria (e.g., non-polarised molecules, single functional group structures, 
etc.). In practice, the scope of QSAR prediction is limited to experienced case by case 
evaluation. 
Further information is available from Commission technical guidance on risk assessment, 
respective of new (Directive 93/67/EEC) existing (Regulation 1488/94) and biocide (Directive 
98/8/EC) substances (http://ecb.jrc.it/). 
5.4.00  BIOACCUMULATION 
5.4.10  Bioconcentration Factor BCF 
Species Report the species used in the test. 
Type of test The type of test should be stated 'ST' (Static), 'SS' (Semi-Static) or 'FT' 
(Flow-Through). 
Concentration(s) Report the concentrations used in mg/l or mg/kg as appropriate. 
of test substance 
Duration of the test Report the duration in days. 
Method of The applied calculation method should be stated 'SS' (Steady State) of K  
calculation  (Kinetic). 
of BCF 
Steady state Concentration in organism in mg/kg after x days 
 Uptake period, x days and no. of samples, y 
 Depuration period, n days and no. of samples. 
Kinetic Uptake rate constant (K1) in hr-1 
 Depuration rate constant (K2) in hr-1 
 Depuration half life in days. 
Bioconcentration Factor 
Whole body State whether dry or wet weight basis. 
Lipid 
Results Tabulate the data used to calculate BCF 
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Steady state wet dry lipid tissue conc. 
weight weight wet weight 
BCF whole body 
BCF edible 
BCF organ specific 
Kinetic method Construct a similar table as for A Steady state. 
% Loss in conc. It is essential to have information on loss so as to be able to estimate the  
in test period exposure. 
Identity and conc. These must be recorded together with any dispersion techniques used. 
of auxiliary If such devices are used proper solvent controls must be run in parallel  
solvents with the test series. 
Water hardness This must determined and reported since it can have a significant effect 
on solubility and toxicity. 
Test (solution) These should be determined and reported. 
temperature and pH 
Method Report the method used. 
Body responsible Select the Testing Facility from the look-up list provided in SNIF, by  
for test entering the appropriate code. 
Comments Comments should be made on any aspects of the test which may have an 
influence on the results. Comments should be full but concise 
 
5.5.00  ADDITIONAL ECOTOXICOLOGICAL TESTS 
General 
Any additional ecotoxicological tests should be reported here; e.g. bioconcentration factor and/or 
other accumulation data, photodegradation. Minimum information to be reported are: end point 
investigated; description of the essential features of the test method; results; test procedure used; 
body responsible for the test; comments. 
The results of photodegradation studies and any other tests not covered in previous sections 
should be entered in this section. In all cases, it is recommended that wherever possible a format 
that can be adapted from those in earlier sections be used for reporting. When reporting 
additional toxicity studies on waste water treatment bacteria, the type of bacteria used must be 
specified, e.g. nitrifying or luminescent. 
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SECTION A6 POSSIBILITY OF RENDERING THE SUBSTANCE 
HARMLESS 
 
6.1.00  FOR INDUSTRY/SKILLED TRADES 
Indicate the general standard phrases and related codes to categorize the recommended 
possibilities for rendering the substance harmless and provide detailed technical information, if 
available. For standard phrases and codes see Annex 5 of this guidance. 
6.1.10  Possibility of Recovery/Recycling of the Substance 
Indicate possibilities for recycling of the used substance at normal use of the substance, 
quantities involved in spills and possibilities for recovery following spillage, and possibilities for 
collection of residues and/or contaminated substance and its container by the manufacturer or 
importer. 
6.1.20  Possibility of Neutralisation (of any potentially hazardous effects). 
Of particular importance to substances which are classified as hazardous. Possible chemical 
treatment(s) which will render the substance harmless should be indicated e.g. oxidation, 
hydrolysis, acid treatment, alkali-treatment, water-treatment, etc. If unknown, it should be 
justified. Comments made in section 2.3.10 should not be repeated in this section. 
6.1.30  Possibility of Destruction 
Controlled E.g. landfill, extensive dilution (to be specified) before discharge to 
discharge surface water. 
Incineration Waste gas treatment should be indicated if necessary. Conditions for 
incineration of potential dioxin-producing compounds should be given. 
Water purification Pre-treatment before discharge to sewage works should be mentioned as 
system should recommended concentrations and any effects on the operation of
 the sewage works. Methods for recovery of the substance in order to
 prevent contamination of sewage works should also be given. 
Others 
 
6.2.00 FOR THE PUBLIC AT LARGE 
For guidance see notes under section 6.1.00. 
6.2.10  Possibility of Recovery/Recycling 
6.2.20  Possibility of Neutralisation (of any potentially hazardous effects) 
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6.2.30  Possibility of Destruction 
Indicate how the public may dispose of the substance or preparations containing it. 
Controlled  
discharge 
Incineration 
Water purification 
system 
Others 
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 SECTION A7 RISK ASSESSMENT  
 
7.0.00  RISK ASSESSMENT 
General 
The risk assessment will be carried out by the Competent Authority. The notifier may submit on 
a voluntary basis a risk assessment of the notified substance. The risk assessment should be 
conducted according to the principles laid down in Directive 93/67/EEC. Supplementary detailed 
information helpful in carrying out a risk assessment are laid down in the technical guidance 
documents for new substances and for existing substances. Details on where to obtain the 
technical guidance documents are available from the Competent Authority. 
The risk assessment should include the following information: 
- hazard identification of the intrinsic hazardous properties of the substance (physico-
chemical, toxicological and ecotoxicological properties); 
- exposure assessment for the human population (i.e. workers, consumers and man exposed 
indirectly via the environment) and for the different environmental compartments likely to 
be exposed to the substance, based on levels derived from measured data or estimated using 
standardized scenarios; 
- comparison of information on hazardous properties and exposure levels in order to 
characterise the degree of risk posed by the substance to human health or to the 
environment; 
- integrated conclusions, separately for human health and the environment, including one or 
more of the type of conclusions set out in article 3 of Directive 93/67/EEC. 
Guidance with regard to the format of the risk assessment (summary) report for notified 
substances is provided in document XI/133/94-Final available from the Competent Authority. 
Annex 1 of the document describes the format of the risk assessment report and Annex II give 
guidance how to complete the risk assessment report 
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SECTION B DECLARATION CONCERNING THE UNFAVOURABLE 
EFFECTS OF THE SUBSTANCE IN TERMS OF THE USES 
ENVISAGED 
When a risk assessment has been provided this section can be omitted. 
This declaration should be concise and is intended to take into account all potential dangers 
including those not covered or identified by the classification and labelling given under Section 
C. Indications for possible danger not tested so far should also be mentioned, e.g. indications for 
possible carcinogenic or mutagenic properties, for sensitisation by inhalation. All entries should 
be checked for consistency with the test results. 
 
SECTION C PROPOSED CLASSIFICATION AND LABELLING 
This section should include the classification and labelling proposed by the notifier; it should be 
consistent with the test results and with the rules and guidance for classification and labelling 
laid down in the Directive. Indicate in the classification all such markings as derived from the 
tests so far per-formed, including those which will not appear on the label due to the precedence 
rules. The classifications "carcinogenic", "mutagenic", and/or "toxic to reproduction" should be 
specified to the adequate category. 
When the labelling of the marketed product differs from the proposed labelling of the substance 
itself because of difference in nature (e.g. in solution in stead of pulverized), specify also the 
labelling of the substance in marketed condition. 
Not fully tested substances (submitted with a reduced notification) should bear, in addition to the 
label deriving from the tests already carried out, the warning: "Caution - substance not yet fully 
tested". 
 
SECTION D PROPOSALS FOR ANY RECOMMENDED PRECAUTIONS 
RELATING TO THE SAFE USE OF THE SUBSTANCE; 
PROPOSED SAFETY DATA SHEET 
For dangerous substances only, include a safety data sheet in accordance with Directive 
91/155/EEC. Attach as an annex, do not enter additional text or data in this section. 
To enable professional users in particular to take the necessary measures as regards the 
protection of the environment and health and safety at the workplace. Before the first delivery of 
a dangerous substance, any manufacturer, importer or distributor shall communicate to the 
recipients this safety data sheet. The sheet should contain the information necessary for 
protection of man and the environment. All information in the safety data sheet should be 
checked for consistency with the test results reported in the summary. 
Although not required, it is recommended to submit also a safety data sheet for non-dangerous 
substances. 
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ANNEX 1 EXPLANATORY NOTE WITH REGARD TO THE 
SECTIONS OF ANNEX VII TO COMPLETE FOR A 
(REDUCED) NOTIFICATION 
Depending on the quantity of the substance marketed in the EEA the following information 
should be provided and the relating sections to be filled in. 
 
1 A notification according to Annex VII A: Base set dossier (> 1000 kg/year/notifier): 
Section 0, Al, A2, A3, A4, A5, A6, B, C, D, E. 
Sections A4.4 10 and A5.3. 10 of the summary form are at this moment for the record. 
Any already available information about the reproductive toxicity and 
adsorption/desorption must be reported in these sections. 
 
2 A notification according to Annex VII B: reduced base set notification (100-1000 
kg/year/manufacturer): 
Sections 0, Al, A2, A6, B, C, D, E. 
From sections A3, A4 and A5 at least the following tests: 
A3.0.00, A3.0.10, A3.0.20, A3.0.60, A3.0.80, A3.0.90, A3.1.00 
A4. 1. 10 (or A4.1.20), A4.1.50, A4.1.60, A4.1.70, A4.3. 10 
A5.2.11 
Depending on national provisions also information on vapour pressure (section A3.0.40) 
and/or acute Daphnia toxicity (section A5.1.02) might be requested at this level. 
 
3 A notification according to Annex VII C: reduced base set notification (10-100 
kg/year/manufacturer): 
Sections 0, Al, A2, A6, B, C, D, E.  
From sections A3 and A4 at least the following tests:  
A3.0.00, A3.0.90, A3.1.00 A4. 1. 10 (or A4.1.20). 
 
4 Polymers (Annex VII D) 
Directive 93/105/EEC contains a specific test strategy for polymers. In addition to the test 
package, in analogy to Annex II of Directive 67/548/EEC, it comprises a concept for 
grouping polymers into families of polymers (family approach) and provides a reduced 
test package for polymers fulfilling specific criteria. A guidance document on the 
notification of polymers (currently XI/584/93 rev. 2) is available from the Competent 
Authority. 
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C.1  Polymers with standard test package 
C.1.1 Annex VII D, C.1.1, base set for polymers  
(> 1000 kg/year/manufacturer): 
In addition to the information and test referred to in Annex VII A, the following polymer-
specific information is required: 
From sections Al, A2 and A3 the following tests: 
A1.3.10.120, A1.3.10.130, A1.3.30, A1.3.32, A1.3.33 
A2.1.35 
A3.1.60 
C.1.2 Annex VII D, C.1.2 reduced base set for polymers 
(100-1000 kg/year/manufacturer): 
In addition to the information and test referred to in Annex VII B, the following polymer-
specific information is required: 
From sections Al, A2 and A3 the following tests: 
A1.3.10.120, A1.3.10.130, A1.3.30, A1.3.32, A1.3.33  
A2.1.35 A3.1.60. 
C.1.3 Annex VII D, C.1.3 reduced base set for polymers  
(10-100 kg/year/manufacturer): 
In addition to the information and test referred to in Annex VII C, the following polymer-
specific information is required: 
From sections A1 and A2 the following tests: 
A1.3.10.120, A1.3.10.130, A1.3.30, A1.3.32, A1.3.33 
A2.1.35 
 
C.2  Polymers for which a reduced test package is acceptable 
Under certain conditions the base set test package for polymers can be reduced. Substances with 
a high number-average molecular weight, a low content of low molecular weight species and a 
low solubility/extractivity will be regarded as being non-bioavailable. 
Consequently, the following criteria shall be used to determine the polymers for which a reduced 
test package is acceptable: 
1. High number-average molecular weight (Mn); 
2. Extractivity/Solubility in water (A.3.0.60) 
 < 10 mg/l excluding any contribution from additives and impurities; 
3. Less than 1% with M <1000: the percentage refers only to molecules (components) 
directly derived from and including monomer(s), excluding other components e.g. 
additives or impurities; if all criteria are fulfilled, the polymer is regarded as polymer for 
which a reduced test package is acceptable. In the case of polymers placed on the 
Community market in amounts <1000 kg/year/manufacturer or total quantities of <5000 
kg it is sufficient that criteria 1 and 2 are fulfilled for the polymer to be considered a 
polymer for which a reduced test package is acceptable. If it is not possible to prove the 
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criteria with the assigned tests, the notifier has to demonstrate compliance with the 
criteria by other means. 
 
C.2.1 Annex VII D, C.2.1 (RTP) 
(> 1000 kg/year/manufacturer): 
Sections 0, Al, A2, A6, B, C, D, E 
From section A3 the following tests: 
A.3.0.00, A.3.0.10, A.3.0.30, A.3.0.60, A.3.1.00, A.3.1.10, A.3.1.20, A.3.1.50, A.3.1.60 
Section A4: 
On a case by case basis, some tests may be required by the Chemical Substance Bureau, without 
delaying the acceptance of the notification, depending on the presence of reactive groups, 
structural/physical characteristics or knowledge of the properties of low molecular components 
of the polymer or exposure potential, namely tests for inhalation toxicity if a potential of such 
exposure exists. 
Section A5: 
On a case by case basis, some tests may be required by the Chemical Substance Bureau, without 
delaying the acceptance of the notification, depending on the presence of reactive groups, 
structural/physical characteristics or knowledge of the properties of low molecular components 
of the polymer or exposure potential. 
The following additional tests may be required in certain cases: 
 light-stability, if the polymer is not specifically light-stabilized 
 long-term extractivity (leachate test) 
Depending on the results of this test, any other appropriate test on the leachate may be requested 
on a case by case basis. 
 
C.2.2 Annex VII D, C.2.2 (RTP) 
(10-1000 kg/year/manufacturer): 
Sections 0, A1, A2, A6, B, C, D, E 
From section A3 the following tests: 
A.3.0.00, A.3.0.10, A.3.0.60, A.3.1.00 
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ANNEX 2 INDUSTRIAL CATEGORY: 
INDUSTRY IN WHICH THE SUBSTANCE IS USED 
1 Agricultural industry 
e.g. Plant protection products; fertilisers. 
2 Chemical industry: basic chemicals 
e.g. Solvents; pH-regulating agents (acids, alkalis). 
3 Chemical industry: chemicals used in synthesis 
e.g. Intermediates (including monomers); process regulators. 
4 Electrical/electronic engineering industry 
e.g. Electrolytes; semiconductors.  
Not galvanics; electroplating agents. 
5 Personal/domestic 
e.g. Consumer products such as detergents (including additives); cosmetics; non-
agricultural biocides for domestic use. 
6 Public domain 
e.g. Professional products used in public areas such as non-agricultural biocides, cleaning 
agents; office and office machinery products such as correction fluids, printing inks. 
7 Leather processing industry 
e.g. Dyestuffs; tanning auxiliaries. 
8 Metal extraction refining and processing industry 
e.g. Heat transferring agents; electroplating agents. 
9 Mineral oil and fuel industry 
e.g. Gasoline; motor oil; gear oil; hydraulic fluid; colouring agents; fuel additives; 
antiknock agents; waste oil detoxification agents. 
10 Photographic industry 
e.g. Antifogging agents; sensitisers. 
11 Polymers industry 
e.g. Stabilisers; softeners; antistatic agents; dyestuffs. 
12 Pulp, Paper and board industry 
e.g. Dyestuffs; toners. 
13 Textile processing industry 
e.g. Dyestuffs; flame retardants. 
14 Paints, lacquers and varnishes industry 
e.g. Solvents; viscosity adjustors; dyestuffs; pigments. 
15 Engineering industry: civil and mechanical  
e.g. Agents used in construction work; agents used in automobile, aircraft and ship 
building. 
999 Other 
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Note: 
The function category 'Others', previously numbered 0 (zero), is now numbered 999. The number 
0 is no longer used and will not be reassigned. 
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ANNEX 3 FUNCTION CATEGORIES 
1 Absorbents and adsorbents 
Materials used to absorb or adsorb gases or liquids: filter materials/media; molecular 
sieves; silica gel etc 
2 Adhesives, binding agents 
Materials which are applied to two surfaces causing them to adhere: dispersion-based 
adhesives; hotmelt; resins for polymer-based hardening adhesives; solvent based 
adhesives. 
3 Aerosol propellants 
Compressed or liquefied gases within which substances are dissolved or suspended and 
expelled from a container upon discharge of the internal pressure through expansion of 
the gas. 
4 Anti-condensation agents 
Substances used to avoid condensation on surfaces and in the atmosphere: anti-dim 
agents; condensation removers. 
5 Anti-freezing agents 
Substances used to prevent and remove ice formation: antifreeze liquids; de-icing agents. 
6 Anti-set-off anti-adhesive agents 
Substances used to prevent set-off and adhesion: spraying powder and anti-set-off 
additives for printing; oils and waxes for laths and shuttering; casting slip etc 
7 Anti-static agents 
Substances used to prevent or reduce the tendency to accumulate electrostatic charges: 
anti-static additives; substances for surface treatment against static electricity. 
8 Bleaching agents 
Substances used to whiten or decolourise materials. 
Not: cosmetics; photographic bleaches; optical brighteners. 
9 Cleaning/washing agents and additives 
Substances used to remove dirt or impurities from surfaces. 
Sub-categories: detergents; soaps; dry cleaning solvents; optical brighteners in detergents. 
10 Colouring agents 
Substances used to impart their colour to other materials. 
Sub-categories: dyestuffs; pigments (including toners); colour forming agents; 
fluorescent brighteners (but see below re detergents). 
Not: cosmetics; food colours; photo-chemicals; optical brighteners used exclusively in 
detergents; reprographic agents. 
11 Complexing agents 
Substances used to combine with other substances (mainly metal ions) to form 
complexes. 
12 Conductive agents 
Materials used to conduct electrical current. 
Sub-categories electrolytes; electrode materials. 
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13 Construction materials and additives 
Substances used in building materials and constructional articles: wall construction 
materials; road surface materials; ceramic, metal, plastic and wooden construction 
materials. 
14 Corrosion inhibitors 
Substances used to prevent corrosion: corrosion inhibiting additives; rust preventives. 
15 Cosmetics 
Substances used as components of cosmetic and toiletry formulations 
16 Dust binding agents 
Substances used to control finely divided solid particles of powdered or ground materials 
to reduce their discharge into the air. 
17 Electroplating agents 
Substances used as a source for a layer of metal deposited on another surface; or that aid 
such a deposition. 
18 Explosives 
Substances or mixtures that are characterised by chemical stability but that may be made 
to undergo chemical change, rapidly producing a large quantity of energy and gas 
accompanied by bursting or expansion.  
Sub-categories: blasting agents; detonators; incendiaries. 
19 Fertilisers 
Substances used to supply chemical elements needed for plant nutrition. 
20 Fillers 
Relatively inert, and normally non-fibrous, finely divided substances added to elastomers, 
plastics, paints, ceramics etc., usually to extend volume which may improve desired 
properties such as whiteness, lubricity, density or tensile strength. 
21 Fixing agents 
Substances used to interact with a dye on fibres to improve fastness. 
22 Flame retardants and fire preventing agents 
Substances incorporated into, or applied to the surface of, materials to slow down or 
prevent combustion. 
23 Flotation agents 
Substances used to concentrate and obtain minerals from ores: flotation oil; flotation 
depressants. 
24 Flux agents for casting 
Substances used to promote the fusing of minerals or prevent oxide formation. 
25 Foaming agents 
Substances used to form a foam or cellular structure in a plastic or rubber material: 
physically by expansion of compressed gases or vaporisation of liquid, or chemically by 
decomposition evolving a gas. 
Sub-categories: chemical or physical blowing agents; frothers. 
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26 Food/feedstuff additives 
Substances used in food or animal feedstuffs to produce or enhance taste, odour or colour 
or to improve conservation. 
27 Fuels 
Substances used to evolve energy in a controlled combustion reaction 
Sub-categories: gasoline; kerosine; gas oil; fuel oil; petroleum gas; non-mineral oil. 
28 Fuel additives 
Substances added to fuels. 
Sub-categories: anti-fouling agents; antiknock agents; deposit modifiers; fuel oxidizers. 
29 Heat transferring agents 
Substances used to transmit or to remove heat from a material. 
Sub-categories cooling agents; heating agents. 
30 Hydraulic fluids and additives 
Fluids used for transmitting pressure. 
31 Impregnation agents 
Substances used to admix with solid materials, which retain their original form: 
impregnating agents for leather, paper, textile and wood. 
Not: flame retardants; conserving agents; biocides. 
32 Insulating materials 
Agents used to prevent or inhibit the flow of electrical current, heat or light or the 
transmission of sound. 
33 Intermediates 
Substances used for synthesis of other chemicals. 
Sub-categories: monomers; pre-polymers. 
34 Laboratory chemicals 
Substances used in laboratories for analytical purposes. 
35 Lubricants and additives 
Substances entrained between two surfaces and thereby used to reduce friction: oils; fats; 
waxes; friction reducing additives. 
36 Odour agents 
Substances used to produce, enhance or mask odour. 
Not: food additives; cosmetics. 
37 Oxidizing agents 
Substances that give up oxygen easily, remove hydrogen from other substances, or accept 
electrons in chemical reactions, and are used for such purposes. 
38 Plant protection Products. agricultural 
Active ingredients and preparations containing one or more active ingredients, intended 
to protect plants or plant products against harmful organisms or prevent the action of such 
organisms, influence the life processes of plants, preserve plant products, destroy 
undesirable plants or destroy parts of plants. 
Not: nutrients; fertilisers. 
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39 Biocides non-agricultural 
Active substances and preparations containing one or more active substances, intended to 
destroy, deter, render harmless, prevent the action of or otherwise exert a controlling 
effect on any organism which has an unwanted presence for man, or a detrimental effect 
for man, his activities or the products he uses or produces; or for animals or for the 
environment. 
Sub-categories: disinfectants, preservative products, pest control products, specialist 
biocides. 
Not: plant protection products; veterinary products. 
40 pH-regulation agents 
Substances used to alter or stabilise the hydrogen ion concentration (pH): acids; alkalis; 
buffers. 
41 Pharmaceuticals 
Substances used as active ingredients in medicinal preparations. 
Sub-category: veterinary medicines. 
42 Photochemicals 
Substances used to create a permanent photographic image. 
Sub-categories: desensitisers; developers; fixing agents; photosensitive agents; 
sensitisers; anti-fogging agents; light stabilisers; intensifiers. 
43 Process regulators 
Substances used to regulate the speed of a (chemical) process. 
Sub-categories: accelerators; activators; catalysts; inhibitors; siccatives; anti-siccatives; 
Cross-linking agents; initiators; photo-initiators etc 
44 Reducing agents 
Substances used to remove oxygen, hydrogenate or, in general, act as electron donors in 
chemical reactions. 
45 Reprographic agents 
Substances used to reproduce a permanent image. 
Sub-categories: toner for photocopying machines; toner additives. 
46 Semiconductors 
Substances having resistivities that are between those of insulators and metals, and are 
usually changeable by light, heat or electrical or magnetic field, or generate electromotive 
force upon the incidence of radiant energy. 
Sub-categories: semiconductors; photovoltaic agents. 
47 Softeners 
Substances used for softening materials to improve feel, to facilitate finishing processes 
or to impart flexibility or workability. 
Sub-categories: coalescing agents; bates (leather technology); devulcanising agents; 
emollients; swelling agents; water softeners; plasticisers 
48 Solvents 
Substances used to dissolve, thin, dilute and extract: extraction agents; solvents and 
thinners for paints, lacquers, adhesives and other materials. 
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49 Stabilisers 
Substances used to prevent or slow down spontaneous changes in, and aging of, 
materials. 
Sub-categories: antioxidants; heat stabilisers; light stabilisers; scavengers; charge 
stabilisers. 
50 Surface-active agents 
Substances used to lower the surface and/or interfacial tension of liquids and promote 
cleaning, wetting, dispersion etc 
51 Tanning agents 
Substances used for treating hides and skins. 
52 Viscosity adjustors 
Substances used to modify the flow characteristics of other substances, or mixtures, to 
which they are added. 
Sub-categories: pour point depressants; thickeners; thixotropic agents; turbulence 
supressors; viscosity index improvers. 
53 Vulcanising agents 
Substances added to rubber to aid and hasten vulcanisation: vulcanising accelerators and 
vulcanising assistants. 
54 Welding and soldering agents 
Materials used for welding and soldering; electrodes; flux; powdered metal; wire etc.. 
999 Others 
Substances whose technical functions are not described elsewhere. 
Note: 
The function category 'Others', previously numbered 0 (zero), is now numbered 999. The number 
0 is no longer used and will not be reassigned. 
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ANNEX 4 EXAMPLES ILLUSTRATING THE USE OF THE 
INDUSTRIAL (ANNEX 1) AND FUNCTION (ANNEX 3) 
CATEGORIES 
1. Dyestuff for artificial fibres/fabrics Use category: Annex I category 13 (Textile 
processing industry). 
Desired effects: Annex II category 10 (Colouring agents; sub-category: dyestuffs). 
'Detailed information' should include an outline of the formulation and dyeing processes, 
degree of fixation etc., as appropriate. 
2. Hair conditioner 
Use category: 
Annex I category 5 (Personal/domestic). 
Desired effects: 
Annex II category 15 (Cosmetics). 
3. Pesticide intermediate 
Use category: 
Annex I category 3 (Chemical industry: chemicals used in synthesis). 
Desired effects: 
Annex II category 33 (Intermediates). 'Detailed information' should include an outline of 
the process; frequency and duration of synthesis. 
4. Fungicide for cereal crops 
Use category: 
Annex I category 1 (Agricultural industry). 
Desired effects: 
Annex II category 38 (Plant protection products, agricultural). 'Detailed information' 
should include information on target and/or protected species; mode and frequency of 
application. Formulation data - type, how prepared etc. - would also be useful. 
5. Disinfectant 
Use categories: 
Annex I category 1 (Agricultural industry). 20% 
Annex I category 5 (Personal/domestic). 5% 
Annex I category 6 (Public domain). 75% 
Desired effects: 
Annex II category 39 (Biocides, non-agricultural; sub-category: disinfectants). 'Detailed 
information' should include information on mode and frequency of use. 
6. Blasting agent (explosive) 
Use category: 
Annex I category 999 (Others: stone quarrying industry). 
Desired effects: 
Annex II category 18 (Explosives; sub-category: blasting agents). 
7. Additive: flame retardant for polyurethane foams and polyester textiles 
Use categories: 
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Annex I category 11 (Polymers industry). 
Annex I category 13 (Textile processing industry). 
Desired effects: 
Annex II category 22 (Flame retardants and fire preventing agents). 
8. Additive to photocopier toner 
Use categories: 
Annex I category 6 (Public domain). 
Annex I category 12 (Pulp, paper and board industry). 
Desired effects: 
Annex II category 45 (reprographic agents; sub-category: toner additives). 
9. Inert liquid with multiple uses 
Use categories: 
Annex I category 2 (Chemical industry: basic chemicals). 15% 
Annex I category 4 (Electrical/electronic engineering industry). 80% 
Annex I category 999 (Other: medical diagnostics). 5% 
Desired effects: 
Annex II category 29 (Heat transferring agents). 
Annex II category 999 (Other: 
a. test liquid in electronic industry; 
b. separation of liquids during transport or analysis). 
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ANNEX 5 CATEGORIES OF RECOMMENDED MEASURES FOR 
RENDERINGTHE SUBSTANCE HARMLESS PROVIDED 
IN SECTION 6 
A: Methods for substances used by the industry 
B: Methods for substances used by the public 
C: Both 
Recovery 
[610 Recovery, not specified] 
611 Recovery by mechanical collection 
612 Recovery by recycling 
613 Recovery by chemical purification 
614 Recovery by distillation 
615 Recovery by sublimation 
616 Recovery by evaporisation 
617 Recovery by dehydration [1 condensation] 
618 Recovery by extraction 
619 Recovery by adsorption 
620 Recovery by absorption 
621 Recovery by precipitation followed by filtration 
622 Recovery by filtration 
622 Recovery by solid/liquid separation 
623 Recovery by special techniques (notifier to specify) 
Neutralisation 
[630 Neutralisation, not specified] 
631 Neutralisation by acid-treatment 
632 Neutralisation by alkali-treatment 
633 Neutralisation by water treatment 
634 Neutralisation by special techniques (notifier to specify, e.g. in an installation 
for detoxification/ neutralisation/ dehydration/ sedimentation/ oxidation) 
Removal in treatment plants 
[640 Removal, not specified] 
641 Removal by controlled discharge to a wastewater treatment plant (notifier to 
specify conditions) 
642 Removal by aerobic treatment 
643 Removal by anaerobic treatment 
Landfill 
650  Removal by controlled dumping at a licensed landfill 
Destruction by incinerate 
[660 Incinerate, not specified] 
661 Incinerator with flue gas scrubbing 
662 Incinerate, high temperature-long burn (*) 
663 Incinerate, high temperature-long burn (*) with flue gas scrubbing 
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664 Incinerate in halogen specific incinerator 
665 Incinerate in other specific incinerators (notifier to specify) (*) minimum 
temperature of 1200 °C, at least 2 seconds' residence time, excess oxygen 
Other destructive techniques 
671 Pyrolysis 
672 Destructive distillation 
673 Destruction by hydrolysis 
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ANNEX 6 INFORMATION THAT MAY BE REQUIRED FOR A 
REQUEST FOR A PROCESSORIENTATED RESEARCH 
AND DEVELOPMENT EXEMPTION 
The following points should be addressed by the applicant, where applicable: 
1. a) What is the chemical identity of the substance i.e. structure, IUPAC name, CAS 
number, impurities, essential additives, spectral data etc? 
b) What is the envisaged use of the substance? 
c) What R & D work has already been carried out either by yourself or, if 
appropriate, by the customers involved in the R & D programme (e.g. internally or 
under the <100kg per annum scientific R & D exemption)? 
 
2. a) What is your justification for wanting to use this exemption (including an 
assurance that you do not currently know whether you can achieve the desired 
effect and that you need to carry out research and development to do so)? 
b) What additional information will be gained through the proposed R & D 
programme? What other methods have been considered for obtaining this 
information? 
c) Please give a summary of the R & D plan, including the process to be 
investigated, the timetable and a proposed start date. 
d) Which parameters will be investigated? 
e) What is the justification for the quantity involved in the proposed R & D 
programme (including justification for the number of batches and quantity per 
batch etc)? 
3. a) What is the name and address of the manufacturer of the substance (if not the 
applicant)? 
b) Which customers will receive the substance and why and how much will each 
customer receive (please provide names, addresses and contact names)? 
4. a) Have you made an application to any other Member States? If so please provide 
details including the status of these applications. 
Either at the time you write requesting an exemption or once we are satisfied with your 
justification and grant an exemption please provide: 
5. a) confirmation that the substance, or any preparation containing it, will only be 
handled by the customers staff under controlled conditions and will not be made 
available to the general public; 
6. a) information on how customer(s) ensure protection of people and the environment 
(e.g. by the provision of an adequate label-including the phrase "Caution-
substance not yet fully tested"-disposal procedures etc); 
7. a) any test data that is already available on the substance (final results only); 
 b) details of any tests you intend to carry out; 
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8. a) estimated date of the corresponding notification; and 
9. a) information on whether you intend to use the substance to produce articles and 
whether these would be made available to the general public. 
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 The mission of the JRC is to provide customer-driven scientific and technical support 
for the conception, development, implementation and monitoring of EU policies. As a 
service of the European Commission, the JRC functions as a reference centre of 
science and technology for the Union. Close to the policy-making process, it serves the 
common interest of the Member States, while being independent of special interests, 
private or national. 
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